Included in the statement of cash flows cash and cash equivalents is $1,576\u00a0of restricted cash as of\u00a0\u00a0 November 30, 2023, as of May 31, 2023.\u00a0\u00a0
\n "}]},{"name":"rpt:f-780","factDimensions":{"xbrl:concept":"us-gaap:RestrictedCashCurrent","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1576000","decimals":-3}]},{"name":"rpt:f-781","factDimensions":{"xbrl:concept":"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 1. Basis of presentation and summary of significant accounting policies
\n\u00a0
\nThe accompanying unaudited\u00a0condensed interim consolidated financial statements (the \u201cfinancial statements\u201d) reflect the accounts of the Company for the quarterly period ended November 30, 2023. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (\u201cSEC\u201d) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the \u201cAnnual Financial Statements\u201d) included in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\u00a0 May 31, 2023\u00a0(the \u201cAnnual Report\u201d). These unaudited condensed interim consolidated\u00a0financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.\u00a0
\n\u00a0
\nThese condensed interim consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company\u2019s accounting policies.
\n\u00a0
\nAll amounts in the unaudited condensed interim consolidated financial statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, unless otherwise indicated.
\n\u00a0
\nCertain items of the comparative figures have been changed to conform to the presentation adopted in the current period.\u00a0
\n\u00a0
\nBasis of consolidation
\n\u00a0
\nSubsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.\u00a0A complete list of our subsidiaries that existed prior to our most recent year end is included in the Annual Report, except for the entities acquired within Note 7\u00a0(Business acquisitions), during the period ended November 30, 2023.
\n\u00a0
\nMarketable securities
\n\u00a0
\nWe classify term deposits and other investments that have maturities of greater than\u00a0three\u00a0months but less than\u00a0one\u00a0year as marketable securities. The fair value of marketable securities is based on quoted market prices for publicly traded securities. Marketable securities are carried at fair value with changes in fair value recorded in the statement of net loss and comprehensive loss, within the line, \u201cNon-operating income (expense)\u201d.
\n\u00a0
\nRestricted cash
\n\u00a0
\nWe classify cash that is\u00a0legally or contractually restricted as to withdrawal or usage, as restricted cash.\u00a0As of November 30, 2023, the Company reported $1,576\u00a0restricted cash related\u00a0to letters of credit and collateral from the acquisition of HEXO Corp. as described in Note 7\u00a0(Business acquisitions).\u00a0
\n\u00a0
\nAssets held for sale
\n\u00a0
\nWe classify capital assets that are available and which are\u00a0probable\u00a0for\u00a0immediate sale in their present condition, which the Company has approved the action or\u00a0plan to sell,\u00a0as\u00a0assets held for sale.\u00a0As of November 30, 2023, the Company reported $736\u00a0assets held for sale related to Kirkland lake property from the acquisition of HEXO Corp. as described in Note 7 (Business acquisitions). Assets held for sale are to be measured at the lower of carrying amount and the fair value less costs to sell. Disposition of assets held for sale are recorded in the statement of net loss and comprehensive loss, within the line, \u201cNon-operating income (expense)\u201d.
\n\u00a0
\nWhen there are changes in circumstances that were previously considered unlikely to occur, and it is decided\u00a0not to proceed with a sale, an asset that was previously classified as\u00a0assets held for sale is reclassified as held and used. The asset is then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount are\u00a0recorded in the statement of net loss and comprehensive loss.\u00a0
\n\u00a0
\nLong-term investments
\n\u00a0
\nInvestments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the \u201cmeasurement alternative\u201d). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, \u201cNon-operating income (expense)\u201d.
\n\u00a0
\n \n \nInvestments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company\u2019s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, adjusted for\u00a0the Company\u2019s share of undistributed earnings or losses, and impairment, if any, within \u201cInterest in equity investees\u201d on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.
\n\u00a0
\nConvertible notes receivable
\n\u00a0
\nConvertible notes receivable\u00a0include various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).
\n\u00a0
\nRevenue
\n\u00a0
\nRevenue is recognized when the control of the promised goods or services, through performance obligation, is transferred/provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations.
\n\u00a0
\nExcise taxes\u00a0remitted\u00a0to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of operations and recognized as a current liability within accounts payable and accrued liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority.
\n\u00a0
\nIn addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.
\n\u00a0
\n \n \nIn determining the transaction price for the sale of goods or services, the Company considers the effects of variable consideration and the existence of significant financing components, if any.
\n\u00a0
\nWe may enter into certain contracts for the sale of goods or services, which provide customers with rights of return, volume discounts, bonuses for volume/quality achievement, and/or sales allowances. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. The inclusion of these items may give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because\u00a0this method provides the most accurate estimation of the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer\u2019s consideration. The estimate is updated at each reporting period date.
\n\u00a0
\nOn July 12, 2022, the Company\u00a0and HEXO Corp. (\"HEXO\") entered into various commercial transaction agreements, as described in\u00a0Note 26\u00a0(Segment reporting), which included\u00a0an advisory services arrangement. The fees associated with the advisory services arrangement were recognized as revenue when such services were provided to HEXO. Any payments that were received for such services in advance of performance were recognized as a contract liability. On June 22, 2023, the Company completed the acquisition of HEXO, as described in\u00a0Note 7 (Business acquisitions), simultaneously terminating the advisory services arrangement and other commercial transactions.
\n\u00a0
\nTransaction (income) costs\u00a0
\n\u00a0
\nThe Company expenses costs net of any gains directly attributable to business acquisitions and classifies these items as transaction (income) costs. These items\u00a0include among other things, legal fees to complete the acquisition, financial advisor and due diligence costs, and transaction related compensation. These items are recognized\u00a0as incurred.
\n\u00a0
\nEarnings (loss) per share
\n\u00a0
\nBasic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a013\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\n\u00a0
\nIn computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three months ended\u00a0 November 30, 2023 and November 30, 2022, the dilutive potential common share equivalents outstanding consisted of the following: 20,939,082 and 16,884,493\u00a0common shares from RSUs, 6,280,065 and 4,674,512 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 77,181,260\u00a0and 23,981,704 common shares for convertible debentures, respectively.
\n\u00a0
\nNew accounting pronouncements not yet adopted
\n\u00a0
\nIn August 2023, the FASB issued ASU 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (\u201cASU 2023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn October\u00a02023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn November\u00a02023, the FASB issued ASU 2023-07,\u00a0Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures,\u00a0which requires public entities to disclose information about their reportable segments\u2019 significant expenses on an interim and annual basis.\u00a0ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU 2023-09 is effective for the Company\u00a0beginning the year ended June 01, 2024.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nNew accounting pronouncements recently adopted
\n\u00a0
\nIn October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (\u201cASU 2021-08\u201d), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The Company adopted the ASU 2021-08 beginning June 1, 2023, however, it\u00a0did not have any impact on our condensed\u00a0interim consolidated financial statements.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-782","factDimensions":{"xbrl:concept":"us-gaap:ConsolidationPolicyTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Basis of consolidation
\n\u00a0
\nSubsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.\u00a0A complete list of our subsidiaries that existed prior to our most recent year end is included in the Annual Report, except for the entities acquired within Note 7\u00a0(Business acquisitions), during the period ended November 30, 2023.
\n\u00a0
\n "}]},{"name":"rpt:f-783","factDimensions":{"xbrl:concept":"us-gaap:MarketableSecuritiesPolicy","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Marketable securities
\n\u00a0
\nWe classify term deposits and other investments that have maturities of greater than\u00a0three\u00a0months but less than\u00a0one\u00a0year as marketable securities. The fair value of marketable securities is based on quoted market prices for publicly traded securities. Marketable securities are carried at fair value with changes in fair value recorded in the statement of net loss and comprehensive loss, within the line, \u201cNon-operating income (expense)\u201d.
\n\u00a0
\n "}]},{"name":"rpt:f-784","factDimensions":{"xbrl:concept":"us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Restricted cash
\n\u00a0
\nWe classify cash that is\u00a0legally or contractually restricted as to withdrawal or usage, as restricted cash.\u00a0As of November 30, 2023, the Company reported $1,576\u00a0restricted cash related\u00a0to letters of credit and collateral from the acquisition of HEXO Corp. as described in Note 7\u00a0(Business acquisitions).\u00a0
\n\u00a0
\n "}]},{"name":"rpt:f-785","factDimensions":{"xbrl:concept":"us-gaap:RestrictedCashCurrent","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis":"tlry:RestrictedCashReservedForLettersOfCreditAndAcquisitionrelatedCollateralMember"},"factValues":[{"value":"1576000","decimals":-3}]},{"name":"rpt:f-786","factDimensions":{"xbrl:concept":"tlry:AssetsHeldforsalePolicyPolicyTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Assets held for sale
\n\u00a0
\nWe classify capital assets that are available and which are\u00a0probable\u00a0for\u00a0immediate sale in their present condition, which the Company has approved the action or\u00a0plan to sell,\u00a0as\u00a0assets held for sale.\u00a0As of November 30, 2023, the Company reported $736\u00a0assets held for sale related to Kirkland lake property from the acquisition of HEXO Corp. as described in Note 7 (Business acquisitions). Assets held for sale are to be measured at the lower of carrying amount and the fair value less costs to sell. Disposition of assets held for sale are recorded in the statement of net loss and comprehensive loss, within the line, \u201cNon-operating income (expense)\u201d.
\n\u00a0
\nWhen there are changes in circumstances that were previously considered unlikely to occur, and it is decided\u00a0not to proceed with a sale, an asset that was previously classified as\u00a0assets held for sale is reclassified as held and used. The asset is then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount are\u00a0recorded in the statement of net loss and comprehensive loss.\u00a0
\n\u00a0
\n "}]},{"name":"rpt:f-787","factDimensions":{"xbrl:concept":"us-gaap:LandAvailableForSale","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis":"tlry:KirklandLakePropertyMember"},"factValues":[{"value":"736000","decimals":-3}]},{"name":"rpt:f-788","factDimensions":{"xbrl:concept":"us-gaap:InvestmentPolicyTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Long-term investments
\n\u00a0
\nInvestments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the \u201cmeasurement alternative\u201d). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, \u201cNon-operating income (expense)\u201d.
\n\u00a0
\n \n \nInvestments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company\u2019s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, adjusted for\u00a0the Company\u2019s share of undistributed earnings or losses, and impairment, if any, within \u201cInterest in equity investees\u201d on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.
\n\u00a0
\n "}]},{"name":"rpt:f-789","factDimensions":{"xbrl:concept":"us-gaap:FinanceLoansAndLeasesReceivablePolicy","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Convertible notes receivable
\n\u00a0
\nConvertible notes receivable\u00a0include various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).
\n\u00a0
\n "}]},{"name":"rpt:f-790","factDimensions":{"xbrl:concept":"us-gaap:RevenueRecognitionPolicyTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Revenue
\n\u00a0
\nRevenue is recognized when the control of the promised goods or services, through performance obligation, is transferred/provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations.
\n\u00a0
\nExcise taxes\u00a0remitted\u00a0to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of operations and recognized as a current liability within accounts payable and accrued liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority.
\n\u00a0
\nIn addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.
\n\u00a0
\n \n \nIn determining the transaction price for the sale of goods or services, the Company considers the effects of variable consideration and the existence of significant financing components, if any.
\n\u00a0
\nWe may enter into certain contracts for the sale of goods or services, which provide customers with rights of return, volume discounts, bonuses for volume/quality achievement, and/or sales allowances. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. The inclusion of these items may give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because\u00a0this method provides the most accurate estimation of the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer\u2019s consideration. The estimate is updated at each reporting period date.
\n\u00a0
\nOn July 12, 2022, the Company\u00a0and HEXO Corp. (\"HEXO\") entered into various commercial transaction agreements, as described in\u00a0Note 26\u00a0(Segment reporting), which included\u00a0an advisory services arrangement. The fees associated with the advisory services arrangement were recognized as revenue when such services were provided to HEXO. Any payments that were received for such services in advance of performance were recognized as a contract liability. On June 22, 2023, the Company completed the acquisition of HEXO, as described in\u00a0Note 7 (Business acquisitions), simultaneously terminating the advisory services arrangement and other commercial transactions.
\n\u00a0
\n "}]},{"name":"rpt:f-791","factDimensions":{"xbrl:concept":"tlry:TransactionCostsPolicyPolicyTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Transaction (income) costs\u00a0
\n\u00a0
\nThe Company expenses costs net of any gains directly attributable to business acquisitions and classifies these items as transaction (income) costs. These items\u00a0include among other things, legal fees to complete the acquisition, financial advisor and due diligence costs, and transaction related compensation. These items are recognized\u00a0as incurred.
\n\u00a0
\n "}]},{"name":"rpt:f-792","factDimensions":{"xbrl:concept":"us-gaap:EarningsPerSharePolicyTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Earnings (loss) per share
\n\u00a0
\nBasic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a013\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\n\u00a0
\nIn computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three months ended\u00a0 November 30, 2023 and November 30, 2022, the dilutive potential common share equivalents outstanding consisted of the following: 20,939,082 and 16,884,493\u00a0common shares from RSUs, 6,280,065 and 4,674,512 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 77,181,260\u00a0and 23,981,704 common shares for convertible debentures, respectively.
\n\u00a0
\n "}]},{"name":"rpt:f-793","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"20939082"}]},{"name":"rpt:f-794","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"16884493"}]},{"name":"rpt:f-795","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"6280065"}]},{"name":"rpt:f-796","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"4674512"}]},{"name":"rpt:f-797","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"6209000"}]},{"name":"rpt:f-798","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"6209000"}]},{"name":"rpt:f-799","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"77181260"}]},{"name":"rpt:f-800","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"23981704"}]},{"name":"rpt:f-801","factDimensions":{"xbrl:concept":"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"New accounting pronouncements not yet adopted
\n\u00a0
\nIn August 2023, the FASB issued ASU 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (\u201cASU 2023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn October\u00a02023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn November\u00a02023, the FASB issued ASU 2023-07,\u00a0Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures,\u00a0which requires public entities to disclose information about their reportable segments\u2019 significant expenses on an interim and annual basis.\u00a0ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU 2023-09 is effective for the Company\u00a0beginning the year ended June 01, 2024.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nNew accounting pronouncements recently adopted
\n\u00a0
\nIn October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (\u201cASU 2021-08\u201d), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The Company adopted the ASU 2021-08 beginning June 1, 2023, however, it\u00a0did not have any impact on our condensed\u00a0interim consolidated financial statements.
"}]},{"name":"rpt:f-802","factDimensions":{"xbrl:concept":"us-gaap:InventoryDisclosureTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 2. Inventory
\n\u00a0
\nInventory consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Plants | \n \u00a0 | \n$ | \n14,908 | \n\u00a0 | \n\u00a0 | \n$ | \n10,884 | \n\u00a0 | \n
| Dried cannabis | \n \u00a0 | \n\u00a0 | \n107,805 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n89,801 | \n\u00a0 | \n
| Cannabis trim | \n \u00a0 | \n\u00a0 | \n- | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n322 | \n\u00a0 | \n
| Cannabis derivatives | \n \u00a0 | \n\u00a0 | \n4,814 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n9,229 | \n\u00a0 | \n
| Cannabis vapes | \n \u00a0 | \n\u00a0 | \n7,076 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,173 | \n\u00a0 | \n
| Packaging and other inventory items | \n \u00a0 | \n\u00a0 | \n17,924 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n19,997 | \n\u00a0 | \n
| Wellness inventory | \n \u00a0 | \n\u00a0 | \n11,395 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n11,164 | \n\u00a0 | \n
| Beverage alcohol inventory | \n \u00a0 | \n\u00a0 | \n52,371 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n27,837 | \n\u00a0 | \n
| Distribution inventory | \n \u00a0 | \n\u00a0 | \n36,409 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n30,144 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n252,702 | \n\u00a0 | \n\u00a0 | \n$ | \n200,551 | \n\u00a0 | \n
\u00a0\u00a0
\n "}]},{"name":"rpt:f-803","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfInventoryCurrentTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Plants | \n \u00a0 | \n$ | \n14,908 | \n\u00a0 | \n\u00a0 | \n$ | \n10,884 | \n\u00a0 | \n
| Dried cannabis | \n \u00a0 | \n\u00a0 | \n107,805 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n89,801 | \n\u00a0 | \n
| Cannabis trim | \n \u00a0 | \n\u00a0 | \n- | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n322 | \n\u00a0 | \n
| Cannabis derivatives | \n \u00a0 | \n\u00a0 | \n4,814 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n9,229 | \n\u00a0 | \n
| Cannabis vapes | \n \u00a0 | \n\u00a0 | \n7,076 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,173 | \n\u00a0 | \n
| Packaging and other inventory items | \n \u00a0 | \n\u00a0 | \n17,924 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n19,997 | \n\u00a0 | \n
| Wellness inventory | \n \u00a0 | \n\u00a0 | \n11,395 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n11,164 | \n\u00a0 | \n
| Beverage alcohol inventory | \n \u00a0 | \n\u00a0 | \n52,371 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n27,837 | \n\u00a0 | \n
| Distribution inventory | \n \u00a0 | \n\u00a0 | \n36,409 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n30,144 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n252,702 | \n\u00a0 | \n\u00a0 | \n$ | \n200,551 | \n\u00a0 | \n
Note 3. Capital assets
\n\u00a0
\nCapital assets consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n46,385 | \n\u00a0 | \n\u00a0 | \n$ | \n30,635 | \n\u00a0 | \n
| Production facility | \n \u00a0 | \n\u00a0 | \n344,593 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n344,627 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n319,749 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n185,422 | \n\u00a0 | \n
| Leasehold improvement | \n \u00a0 | \n\u00a0 | \n8,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,753 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n \u00a0 | \n\u00a0 | \n57,056 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n
| Construction in progress | \n \u00a0 | \n\u00a0 | \n12,794 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,048 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n788,724 | \n\u00a0 | \n\u00a0 | \n$ | \n576,485 | \n\u00a0 | \n
| Less: accumulated amortization | \n \u00a0 | \n\u00a0 | \n(173,637 | \n) | \n\u00a0 | \n\u00a0 | \n(146,818 | \n) | \n
| Total | \n \u00a0 | \n$ | \n615,087 | \n\u00a0 | \n\u00a0 | \n$ | \n429,667 | \n\u00a0 | \n
\u00a0 \u00a0\u00a0
\n \n \n "}]},{"name":"rpt:f-825","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n46,385 | \n\u00a0 | \n\u00a0 | \n$ | \n30,635 | \n\u00a0 | \n
| Production facility | \n \u00a0 | \n\u00a0 | \n344,593 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n344,627 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n319,749 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n185,422 | \n\u00a0 | \n
| Leasehold improvement | \n \u00a0 | \n\u00a0 | \n8,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,753 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n \u00a0 | \n\u00a0 | \n57,056 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n
| Construction in progress | \n \u00a0 | \n\u00a0 | \n12,794 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,048 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n788,724 | \n\u00a0 | \n\u00a0 | \n$ | \n576,485 | \n\u00a0 | \n
| Less: accumulated amortization | \n \u00a0 | \n\u00a0 | \n(173,637 | \n) | \n\u00a0 | \n\u00a0 | \n(146,818 | \n) | \n
| Total | \n \u00a0 | \n$ | \n615,087 | \n\u00a0 | \n\u00a0 | \n$ | \n429,667 | \n\u00a0 | \n
\u00a0Note 4. Leases
\n\u00a0
\nThe table below presents the lease-related assets and liabilities recorded on the balance sheet.
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| \u00a0 | \n Classification on Balance Sheet | \n \u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||
| Assets | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n Capital assets | \n \u00a0 | \n$ | \n57,056 | \n\u00a0 | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n
| Operating lease, right-of-use assets | \n Right of use assets | \n \u00a0 | \n\u00a0 | \n13,551 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,941 | \n\u00a0 | \n
| Total right-of-use asset | \n \u00a0 | \n$ | \n70,607 | \n\u00a0 | \n\u00a0 | \n$ | \n5,941 | \n\u00a0 | \n|
| Liabilities | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Current: | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Current portion of finance lease liabilities | \n Accrued lease obligations - current | \n \u00a0 | \n$ | \n1,336 | \n\u00a0 | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n
| Current portion of operating lease liabilities | \n Accrued lease obligations - current | \n \u00a0 | \n\u00a0 | \n3,707 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,423 | \n\u00a0 | \n
| Non-current: | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Finance lease liabilities | \n Accrued lease obligations - non-current | \n \u00a0 | \n\u00a0 | \n56,010 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n
| Operating lease liabilities | \n Accrued lease obligations - non-current | \n \u00a0 | \n\u00a0 | \n13,964 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,936 | \n\u00a0 | \n
| Total lease liabilities | \n \u00a0 | \n$ | \n75,017 | \n\u00a0 | \n\u00a0 | \n$ | \n10,359 | \n\u00a0 | \n
\u00a0
\n\u00a0
\nThe following table presents the future undiscounted payment associated with lease liabilities as of November 30, 2023:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n Operating | \n \u00a0 | \n\u00a0 | \n Finance | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n||
| 2024 | \n \u00a0 | \n$ | \n4,106 | \n\u00a0 | \n\u00a0 | \n$ | \n4,622 | \n\u00a0 | \n
| 2025 | \n \u00a0 | \n\u00a0 | \n3,295 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,699 | \n\u00a0 | \n
| 2026 | \n \u00a0 | \n\u00a0 | \n3,486 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,782 | \n\u00a0 | \n
| 2027 | \n \u00a0 | \n\u00a0 | \n3,412 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,542 | \n\u00a0 | \n
| Thereafter | \n \u00a0 | \n\u00a0 | \n4,012 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n87,903 | \n\u00a0 | \n
| Total minimum lease payments | \n \u00a0 | \n$ | \n18,311 | \n\u00a0 | \n\u00a0 | \n$ | \n106,548 | \n\u00a0 | \n
| Imputed interest | \n \u00a0 | \n\u00a0 | \n(640 | \n) | \n\u00a0 | \n\u00a0 | \n(49,202 | \n) | \n
| Obligations recognized | \n \u00a0 | \n$ | \n17,671 | \n\u00a0 | \n\u00a0 | \n$ | \n57,346 | \n\u00a0 | \n
\u00a0
\n "}]},{"name":"rpt:f-845","factDimensions":{"xbrl:concept":"tlry:LeaseRelatedAssetsAndLiabilitiesTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| \u00a0 | \n Classification on Balance Sheet | \n \u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||
| Assets | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n Capital assets | \n \u00a0 | \n$ | \n57,056 | \n\u00a0 | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n
| Operating lease, right-of-use assets | \n Right of use assets | \n \u00a0 | \n\u00a0 | \n13,551 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,941 | \n\u00a0 | \n
| Total right-of-use asset | \n \u00a0 | \n$ | \n70,607 | \n\u00a0 | \n\u00a0 | \n$ | \n5,941 | \n\u00a0 | \n|
| Liabilities | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Current: | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Current portion of finance lease liabilities | \n Accrued lease obligations - current | \n \u00a0 | \n$ | \n1,336 | \n\u00a0 | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n
| Current portion of operating lease liabilities | \n Accrued lease obligations - current | \n \u00a0 | \n\u00a0 | \n3,707 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,423 | \n\u00a0 | \n
| Non-current: | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Finance lease liabilities | \n Accrued lease obligations - non-current | \n \u00a0 | \n\u00a0 | \n56,010 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n
| Operating lease liabilities | \n Accrued lease obligations - non-current | \n \u00a0 | \n\u00a0 | \n13,964 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,936 | \n\u00a0 | \n
| Total lease liabilities | \n \u00a0 | \n$ | \n75,017 | \n\u00a0 | \n\u00a0 | \n$ | \n10,359 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n Operating | \n \u00a0 | \n\u00a0 | \n Finance | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n||
| 2024 | \n \u00a0 | \n$ | \n4,106 | \n\u00a0 | \n\u00a0 | \n$ | \n4,622 | \n\u00a0 | \n
| 2025 | \n \u00a0 | \n\u00a0 | \n3,295 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,699 | \n\u00a0 | \n
| 2026 | \n \u00a0 | \n\u00a0 | \n3,486 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,782 | \n\u00a0 | \n
| 2027 | \n \u00a0 | \n\u00a0 | \n3,412 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,542 | \n\u00a0 | \n
| Thereafter | \n \u00a0 | \n\u00a0 | \n4,012 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n87,903 | \n\u00a0 | \n
| Total minimum lease payments | \n \u00a0 | \n$ | \n18,311 | \n\u00a0 | \n\u00a0 | \n$ | \n106,548 | \n\u00a0 | \n
| Imputed interest | \n \u00a0 | \n\u00a0 | \n(640 | \n) | \n\u00a0 | \n\u00a0 | \n(49,202 | \n) | \n
| Obligations recognized | \n \u00a0 | \n$ | \n17,671 | \n\u00a0 | \n\u00a0 | \n$ | \n57,346 | \n\u00a0 | \n
Note 5. Intangible Assets
\n\u00a0
\nIntangible assets consisted of the following items:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Customer relationships & distribution channel | \u00a0 | $ | 620,876 | \u00a0 | \u00a0 | $ | 614,062 | \u00a0 |
| Licenses, permits & applications | \u00a0 | \u00a0 | 370,753 | \u00a0 | \u00a0 | \u00a0 | 366,793 | \u00a0 |
| Non-compete agreements | \u00a0 | \u00a0 | 12,441 | \u00a0 | \u00a0 | \u00a0 | 12,394 | \u00a0 |
| Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | 594,948 | \u00a0 | \u00a0 | \u00a0 | 583,468 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | 1,599,018 | \u00a0 | \u00a0 | $ | 1,576,717 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (229,755 | ) | \u00a0 | \u00a0 | (187,088 | ) |
| Less: impairments | \u00a0 | \u00a0 | (415,844 | ) | \u00a0 | \u00a0 | (415,844 | ) |
| Total | \u00a0 | $ | 953,419 | \u00a0 | \u00a0 | $ | 973,785 | \u00a0 |
\u00a0
\nIncluded in licenses, permits & applications was\u00a0$184,858\u00a0of indefinite-lived intangible assets as of November 30, 2023, compared to $181,093\u00a0as of May 31, 2023.
\n\u00a0
\nExpected future amortization expense for intangible assets as of\u00a0 November 30, 2023 are as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2024 (remaining six months) | \u00a0 | $ | 36,861 | \u00a0 |
| 2025 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 436,812 | \u00a0 |
| Total | \u00a0 | $ | 768,561 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-880","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Customer relationships & distribution channel | \u00a0 | $ | 620,876 | \u00a0 | \u00a0 | $ | 614,062 | \u00a0 |
| Licenses, permits & applications | \u00a0 | \u00a0 | 370,753 | \u00a0 | \u00a0 | \u00a0 | 366,793 | \u00a0 |
| Non-compete agreements | \u00a0 | \u00a0 | 12,441 | \u00a0 | \u00a0 | \u00a0 | 12,394 | \u00a0 |
| Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | 594,948 | \u00a0 | \u00a0 | \u00a0 | 583,468 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | 1,599,018 | \u00a0 | \u00a0 | $ | 1,576,717 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (229,755 | ) | \u00a0 | \u00a0 | (187,088 | ) |
| Less: impairments | \u00a0 | \u00a0 | (415,844 | ) | \u00a0 | \u00a0 | (415,844 | ) |
| Total | \u00a0 | $ | 953,419 | \u00a0 | \u00a0 | $ | 973,785 | \u00a0 |
| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2024 (remaining six months) | \u00a0 | $ | 36,861 | \u00a0 |
| 2025 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 73,722 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 436,812 | \u00a0 |
| Total | \u00a0 | $ | 768,561 | \u00a0 |
Note 6. Goodwill
\n\u00a0
\nThe following table shows the carrying amount of goodwill by reporting units:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| Reporting Unit | \n \u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||
| Cannabis | \n \u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n\u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n
| Distribution | \n \u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n
| Beverage alcohol | \n \u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n
| Wellness | \n \u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n
| Effect of foreign exchange | \n \u00a0 | \n\u00a0 | \n8,746 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,875 | \n\u00a0 | \n
| Impairments | \n \u00a0 | \n\u00a0 | \n(842,431 | \n) | \n\u00a0 | \n\u00a0 | \n(842,431 | \n) | \n
| Total | \n \u00a0 | \n$ | \n2,009,714 | \n\u00a0 | \n\u00a0 | \n$ | \n2,008,843 | \n\u00a0 | \n
\u00a0
\n \n \n "}]},{"name":"rpt:f-908","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfGoodwillTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| Reporting Unit | \n \u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||
| Cannabis | \n \u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n\u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n
| Distribution | \n \u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n
| Beverage alcohol | \n \u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n
| Wellness | \n \u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n
| Effect of foreign exchange | \n \u00a0 | \n\u00a0 | \n8,746 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,875 | \n\u00a0 | \n
| Impairments | \n \u00a0 | \n\u00a0 | \n(842,431 | \n) | \n\u00a0 | \n\u00a0 | \n(842,431 | \n) | \n
| Total | \n \u00a0 | \n$ | \n2,009,714 | \n\u00a0 | \n\u00a0 | \n$ | \n2,008,843 | \n\u00a0 | \n
Note 7.\u00a0Business\u00a0acquisitions
\n\u00a0\u00a0
\nAcquisition of\u00a0Montauk Brewing Company, Inc.
\n\u00a0
\nOn\u00a0\u00a0 November 7, 2022,\u00a0Tilray acquired Montauk Brewing Company, Inc. (\u201cMontauk\u201d), a leading craft brewer based in Montauk, New York, which expanded our distribution network with a strong brand in the tri-state region of the U.S.\u00a0In consideration for the acquisition of Montauk, and after giving effect to post-closing adjustments, the Company paid an aggregate purchase price equal to\u00a0$35,123, which was comprised\u00a0of $ 28,701\u00a0in cash and\u00a0the remainder through\u00a0the issuance of\u00a01,708,521\u00a0shares of Tilray's common stock (having a value of $6,422 at closing). In the event that Montauk\u00a0achieves certain volume and/or EBITDA targets on or before\u00a0 December 31, 2025,\u00a0the stockholders of Montauk shall be eligible to receive additional contingent\u00a0cash consideration of up to $18,000. The Company determined that the closing date fair\u00a0value\u00a0of this contingent consideration was $10,245 based on the inputs disclosed in Note\u00a025\u00a0(Fair value measurements).\u00a0
\n\u00a0
\nThe table below summarizes fair value of the assets acquired and the liabilities assumed at the effective acquisition date.\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash | \u00a0 | $ | 28,701 | \u00a0 |
| Shares | \u00a0 | \u00a0 | 6,422 | \u00a0 |
| Contingent consideration | \u00a0 | \u00a0 | 10,245 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 1,983 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,116 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 467 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 1,570 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 420 | \u00a0 |
| Customer relationships ( years) | \u00a0 | \u00a0 | 18,540 | \u00a0 |
| Intellectual property, trademarks & brands ( years) | \u00a0 | \u00a0 | 13,650 | \u00a0 |
| Goodwill | \u00a0 | \u00a0 | 17,803 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 55,549 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 1,580 | \u00a0 |
| Long-term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Deferred tax liability | \u00a0 | \u00a0 | 4,851 | \u00a0 |
| Other liabilities | \u00a0 | \u00a0 | 3,750 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 10,181 | \u00a0 |
| Total net assets acquired | \u00a0 | $ | 45,368 | \u00a0 |
\u00a0
\nIn the event that the Montauk acquisition had occurred on June 1, 2022, the Company would have had additional net\u00a0revenue of approximately $3,100 and $9,000 for the three and six months ended November 30, 2022\u00a0and net loss and comprehensive net loss would have increased by approximately\u00a0$600 and $500 for the three and six months ended\u00a0 November 30, 2022,\u00a0primarily as a result of amortization of the intangible assets acquired. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of Montauk.
\n\u00a0
\n \n \nAcquisition of HEXO Corp.
\n\u00a0
\nOn June 22, 2023, Tilray acquired\u00a0HEXO, a cannabis\u00a0company in Canada (the \u201cHEXO Acquisition\u201d) for the purpose of expanding the Company\u2019s revenue base, production capabilities around certain form factors and growth opportunities with the Redecan brand. In consideration for the HEXO Acquisition, the Company paid a total purchase price equivalent of $93,882, which\u00a0consisted of stock consideration of\u00a0$63,927, settlement of convertible notes receivable of $28,720, the fair value of HEXO stock-based compensation of $1,188\u00a0and the assumption of warrants of $47. In connection with the HEXO Acquisition, each outstanding HEXO common share was exchanged for 0.4352 of a share of Tilray common stock and each outstanding HEXO preferred share was\u00a0exchanged for 0.7805 of a share of Tilray common stock. In the aggregate, the Company issued\u00a039,705,962 shares of Tilray common stock, at a share price of $1.61 per share,\u00a0in connection with the HEXO Acquisition.\u00a0The Company intends to sell HEXO's\u00a0Kirkland lake property and\u00a0has recorded the value of the associated capital assets as an asset held for sale.
\n\u00a0
\nThe Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may be subject to adjustments pending completion of final valuations and post-closing adjustments.\u00a0The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the HEXO Acquisition at the effective acquisition date\u00a0as follows:\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Shares | \u00a0 | $ | 63,927 | \u00a0 |
| Settlement of convertible notes receivable | \u00a0 | \u00a0 | 28,720 | \u00a0 |
| Warrants assumed | \u00a0 | \u00a0 | 47 | \u00a0 |
| Estimated fair value of HEXO stock-based compensation | \u00a0 | \u00a0 | 1,188 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 14,634 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | 1,656 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 7,855 | \u00a0 |
| Asset held for sale | \u00a0 | \u00a0 | 755 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 2,709 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 25,947 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Prepaid expenses | \u00a0 | \u00a0 | 8,384 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 70,634 | \u00a0 |
| Intellectual property, trademarks & brands ( years) | \u00a0 | \u00a0 | 2,680 | \u00a0 |
| Interest in equity investee | \u00a0 | \u00a0 | 3,145 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 138,399 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 44,517 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 44,517 | \u00a0 |
| Total net assets acquired | \u00a0 | $ | 93,882 | \u00a0 |
\u00a0
\nIncluded in accounts payable and accrued liabilities was\u00a0$12,253\u00a0of litigation settlement accruals as of June 22, 2023.\u00a0
\n\u00a0
\nIn the event the HEXO Acquisition had occurred on June 1, 2022, the Company would have had, on an unaudited proforma basis,\u00a0additional net\u00a0revenue of approximately and $7,000 for the three and six months period ended\u00a0 November 30, 2023\u00a0and $20,000\u00a0and $40,000\u00a0for the three and six months period ended November 30,\u00a02022, respectively, and its net loss and comprehensive net loss would have increased by approximately\u00a0 and $1,800 for the three and six months period\u00a0ended November 30,\u00a02023,\u00a0and\u00a0$30,000\u00a0and $60,000\u00a0for the three and six months period ended November 30,\u00a02022, respectively. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of HEXO.
\n\u00a0
\nAcquisition of\u00a0Truss Beverage Co.
\n\u00a0
\nOn August 3, 2023, Tilray acquired the remaining 57.5% equity interest in Truss Beverage Co. (\"Truss\"), a cannabis beverage company, from Molson Coors Canada (\"Molson\").\u00a0 This purchase represents the equity portion of Truss that had not been previously acquired as part of the HEXO Acquisition. The consideration paid by Tilray consisted of\u00a0$74\u00a0() in cash and\u00a0contingent consideration fair valued at $4,181.\u00a0Tilray initially planned to divest Truss' assets and\u00a0recorded the value of the associated capital assets and lease obligations as an asset held for sale. Tilray has agreed to pay Molson as contingent consideration an amount equal to 57.5% of any proceeds from any divesture, net of any costs and expenses associated with the disposition. During the period ended November 30, 2023, due to a change in circumstance in the Company's ability to sell these assets, they\u00a0were subsequently reclassified as capital assets as the Company has made alternative plans for their utilization. The asset was\u00a0then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount were\u00a0recorded in the statement of net loss and comprehensive loss\u00a0as amortization in cost of goods sold.\u00a0
\n\u00a0
\nThe Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired may be subject to adjustments pending completion of final valuations and post-closing adjustments.\u00a0The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the effective acquisition date\u00a0as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 74 | \u00a0 |
| Investment in equity investees | \u00a0 | \u00a0 | 3,145 | \u00a0 |
| Contingent consideration | \u00a0 | \u00a0 | 4,181 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 6,739 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,038 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 78 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 2,573 | \u00a0 |
| Asset held for sale | \u00a0 | \u00a0 | 2,960 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Intangible assets | \u00a0 | \u00a0 | 296 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 13,684 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 5,408 | \u00a0 |
| Other liabilities | \u00a0 | \u00a0 | 876 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 6,284 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 7,400 | \u00a0 |
\u00a0
\nIn the event that the Truss acquisition had occurred on June 1, 2022 the Company would have had, on an unaudited proforma basis, additional net\u00a0revenue of approximately and $3,000 for the three and six months period ended\u00a0 November 30, 2023\u00a0and $3,300 and $6,300\u00a0for the three and six months period ended November 30,\u00a02022, respectively, and its net loss and comprehensive net loss would have increased by approximately\u00a0 and $700 for the three and six months period\u00a0ended November 30,\u00a02023,\u00a0and\u00a0$500 and $1,200\u00a0for the three and six months period ended November 30,\u00a02022, respectively. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of Truss.
\n\u00a0
\nAcquisition of Craft\u00a0Beverage\u00a0Business Portfolio
\n\u00a0
\nOn September 29, 2023, Tilray acquired a portfolio of craft brands, assets and businesses comprising beer and beverage brands from Anheuser-Busch Companies, LLC, (\"AB\") including breweries and brewpubs associated with them (the \u201cCraft\u00a0Acquisition\u201d). The acquired businesses/brands\u00a0include\u00a0Shock Top,\u00a0Breckenridge Brewery,\u00a0Blue Point Brewing Company, 10\u00a0Barrel Brewing Company,\u00a0Redhook Brewery, Widmer Brothers Brewing,\u00a0Square Mile Cider Company, and HiBall Energy. The Company paid a total purchase price equivalent of $83,658\u00a0in cash, net of a preliminary working capital adjustment at closing of $1,342, which is subject to a final working capital adjustment. As described in Note 12\u00a0(Long-term debt),\u00a0$20,000 was borrowed under the 420 Delayed Draw Term Loan Agreement to fund part of the purchase price paid for the Craft\u00a0Acquisition.
\n\u00a0
\nThe Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may be subject to adjustments pending completion of final valuations and post-closing adjustments.\u00a0The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the Craft Acquisition at the effective acquisition date\u00a0as follows:\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 83,658 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 77 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 22,493 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 573 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 62,614 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 45,496 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 7,677 | \u00a0 |
| Other assets | \u00a0 | \u00a0 | 108 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 139,038 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 2,206 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 1,031 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 1,408 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 44,465 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 6,270 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 55,380 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 83,658 | \u00a0 |
\u00a0
\nIn the event that the Craft\u00a0Acquisition had occurred on June 1, 2022, the Company would have had, on an unaudited proforma basis, additional revenue of approximately $14,000 and $55,000 for the three and six months period ended\u00a0 November 30, 2023\u00a0and $42,000\u00a0and $85,000 for the three and six months period ended November 30,\u00a02022, respectively, and its net loss and comprehensive net loss would have increased by approximately $2,000 and $5,000 for the three and six months period\u00a0ended November 30,\u00a02023,\u00a0and\u00a0$1,400 and $900 for the three and six months period ended November 30,\u00a02022, respectively. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of the Craft\u00a0Acquisition.
\n "}]},{"name":"rpt:f-924","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationConsiderationTransferred1","xbrl:period":"2022-11-07T00:00:00/2022-11-08T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:AcquisitionOfMontaukBrewingCompanyIncMember"},"factValues":[{"value":"35123000","decimals":-3}]},{"name":"rpt:f-925","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireBusinessesGross","xbrl:period":"2022-11-07T00:00:00/2022-11-08T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:AcquisitionOfMontaukBrewingCompanyIncMember"},"factValues":[{"value":"28701000","decimals":-3}]},{"name":"rpt:f-926","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued","xbrl:period":"2022-11-07T00:00:00/2022-11-08T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"tlry:AcquisitionOfMontaukBrewingCompanyIncMember","us-gaap:StatementClassOfStockAxis":"tlry:CommonClass2Member"},"factValues":[{"value":"1708521"}]},{"name":"rpt:f-927","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable","xbrl:period":"2022-11-07T00:00:00/2022-11-08T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:AcquisitionOfMontaukBrewingCompanyIncMember","us-gaap:StatementClassOfStockAxis":"tlry:CommonClass2Member"},"factValues":[{"value":"6422000","decimals":-3}]},{"name":"rpt:f-928","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh","xbrl:period":"2022-11-08T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:AcquisitionOfMontaukBrewingCompanyIncMember"},"factValues":[{"value":"18000000","decimals":-6}]},{"name":"rpt:f-929","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationContingentConsiderationLiability","xbrl:period":"2022-11-08T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:AcquisitionOfMontaukBrewingCompanyIncMember"},"factValues":[{"value":"10245000","decimals":-3}]},{"name":"rpt:f-930","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash | \u00a0 | $ | 28,701 | \u00a0 |
| Shares | \u00a0 | \u00a0 | 6,422 | \u00a0 |
| Contingent consideration | \u00a0 | \u00a0 | 10,245 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 1,983 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,116 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 467 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 1,570 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 420 | \u00a0 |
| Customer relationships ( years) | \u00a0 | \u00a0 | 18,540 | \u00a0 |
| Intellectual property, trademarks & brands ( years) | \u00a0 | \u00a0 | 13,650 | \u00a0 |
| Goodwill | \u00a0 | \u00a0 | 17,803 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 55,549 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 1,580 | \u00a0 |
| Long-term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Deferred tax liability | \u00a0 | \u00a0 | 4,851 | \u00a0 |
| Other liabilities | \u00a0 | \u00a0 | 3,750 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 10,181 | \u00a0 |
| Total net assets acquired | \u00a0 | $ | 45,368 | \u00a0 |
| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Shares | \u00a0 | $ | 63,927 | \u00a0 |
| Settlement of convertible notes receivable | \u00a0 | \u00a0 | 28,720 | \u00a0 |
| Warrants assumed | \u00a0 | \u00a0 | 47 | \u00a0 |
| Estimated fair value of HEXO stock-based compensation | \u00a0 | \u00a0 | 1,188 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 14,634 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | 1,656 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 7,855 | \u00a0 |
| Asset held for sale | \u00a0 | \u00a0 | 755 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 2,709 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 25,947 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Prepaid expenses | \u00a0 | \u00a0 | 8,384 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 70,634 | \u00a0 |
| Intellectual property, trademarks & brands ( years) | \u00a0 | \u00a0 | 2,680 | \u00a0 |
| Interest in equity investee | \u00a0 | \u00a0 | 3,145 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 138,399 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 44,517 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 44,517 | \u00a0 |
| Total net assets acquired | \u00a0 | $ | 93,882 | \u00a0 |
| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 74 | \u00a0 |
| Investment in equity investees | \u00a0 | \u00a0 | 3,145 | \u00a0 |
| Contingent consideration | \u00a0 | \u00a0 | 4,181 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 6,739 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,038 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 78 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 2,573 | \u00a0 |
| Asset held for sale | \u00a0 | \u00a0 | 2,960 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Intangible assets | \u00a0 | \u00a0 | 296 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 13,684 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 5,408 | \u00a0 |
| Other liabilities | \u00a0 | \u00a0 | 876 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 6,284 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 7,400 | \u00a0 |
| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 83,658 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 77 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 22,493 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 573 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 62,614 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 45,496 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 7,677 | \u00a0 |
| Other assets | \u00a0 | \u00a0 | 108 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 139,038 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 2,206 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 1,031 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 1,408 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 44,465 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 6,270 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 55,380 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 83,658 | \u00a0 |
Note 8.\u00a0Convertible notes receivable
\n\u00a0
\nConvertible notes receivable is comprised of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| HEXO Convertible Note | \u00a0 | $ | - | \u00a0 | \u00a0 | $ | 28,720 | \u00a0 |
| MedMen Convertible Note | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | 74,681 | \u00a0 |
| Total convertible notes receivable | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | 103,401 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | - | \u00a0 |
| Total convertible notes receivable, non current portion | \u00a0 | $ | 74,681 | \u00a0 | \u00a0 | $ | 103,401 | \u00a0 |
\u00a0
\nHEXO Convertible Note
\n\u00a0
\nOn June\u00a022, 2023, the Company completed the HEXO Acquisition as described in Note 7 (Business acquisitions). Concurrently with the closing of the HEXO Acquisition, the HEXO convertible note was converted into shares of HEXO.
\n\u00a0
\n \n \nMedMen Convertible Note
\n\u00a0
\nOn August 31, 2021, the Company issued\u00a09,817,061 shares valued at $117,804 to acquire\u00a068% interest in Superhero Acquisition L.P. (\u201cSH Acquisition\u201d), which purchased a senior secured convertible note issued by MedMen (the \"MedMen Convertible Note\"), together with certain associated warrants to acquire Class B subordinate voting shares of MedMen, in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured Overnight Financing Rate (\"SOFR\") plus\u00a06%, with a SOFR floor of\u00a02.5% with any accrued interest being added to the outstanding principal amount. The outstanding principal amount, together with accrued interest\u00a0is to be paid on August 17, 2028, the\u00a0maturity date of the MedMen Convertible Note. SH Acquisition was also granted \u201ctop-up\u201d rights enabling it (and its limited partners) to maintain its percentage ownership (on an \u201cas-converted\u201d basis) in the event that MedMen issues equity securities.\u00a0SH Acquisition\u2019s ability to convert the MedMen Convertible Note\u00a0and exercise the Warrants is dependent upon U.S. federal legalization of cannabis or Tilray\u2019s waiver of such requirement as well as any additional regulatory approvals.\u00a0
\n\u00a0
\nThe\u00a0MedMen Convertible Note was\u00a0based upon the fair value of the\u00a0collateral assets net of disposal costs.\u00a0 In the prior year, the Company used the\u00a0Black-Scholes model using the following assumptions: the risk-free rate of expected life of the convertible note; volatility of\u00a070% based on comparable companies; forfeiture rate of dividend yield of probability of legalization between\u00a00% and\u00a0 and, the exercise price of the respective conversion feature.\u00a0
\n\u00a0
\nThe Company\u00a0did derive any revenue or cash from MedMen's operations, and fully complies with all limitations imposed by applicable U.S. law and regulations in connection with its ownership of the MedMen Convertible Note.\u00a0In addition, the Company did not recognize any\u00a0interest income on the MedMen Convertible Note\u00a0for the three and six\u00a0months ended November 30, 2023, which would have\u00a0increased\u00a0its value.\u00a0
\n "}]},{"name":"rpt:f-1037","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| HEXO Convertible Note | \u00a0 | $ | - | \u00a0 | \u00a0 | $ | 28,720 | \u00a0 |
| MedMen Convertible Note | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | 74,681 | \u00a0 |
| Total convertible notes receivable | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | 103,401 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | - | \u00a0 |
| Total convertible notes receivable, non current portion | \u00a0 | $ | 74,681 | \u00a0 | \u00a0 | $ | 103,401 | \u00a0 |
Note 9. Long term investments
\n\u00a0
\nLong term investments consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Equity investments measured at fair value | \n \u00a0 | \n$ | \n2,534 | \n\u00a0 | \n\u00a0 | \n$ | \n2,144 | \n\u00a0 | \n
| Equity investments under measurement alternative | \n \u00a0 | \n\u00a0 | \n5,500 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,651 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n8,034 | \n\u00a0 | \n\u00a0 | \n$ | \n7,795 | \n\u00a0 | \n
\u00a0 \u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-1057","factDimensions":{"xbrl:concept":"us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Equity investments measured at fair value | \n \u00a0 | \n$ | \n2,534 | \n\u00a0 | \n\u00a0 | \n$ | \n2,144 | \n\u00a0 | \n
| Equity investments under measurement alternative | \n \u00a0 | \n\u00a0 | \n5,500 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,651 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n8,034 | \n\u00a0 | \n\u00a0 | \n$ | \n7,795 | \n\u00a0 | \n
Note 10. Bank indebtedness
\n\u00a0
\nAphria Inc., a subsidiary of the Company,\u00a0has an operating line of credit in the amount of which bears interest at the lender\u2019s prime rate plus 75 basis points. As of November 30, 2023, the Company has drawn on the line of credit. The operating line of credit is secured by a security interest on that certain real property located\u00a0at 265 Talbot St. West, Leamington, Ontario.
\n\u00a0
\nCC Pharma GmbH, a subsidiary of the Company, has \u00a0operating lines of credit for\u00a0\u00a0and\u00a0\u00a0each, which bear interest at\u00a0Euro Short-Term Rate (\"ESTR\") plus 2.50% and Euro Interbank Offered Rate (\"EURIBOR\") plus 4.00%, respectively. As of November 30, 2023, a total of \u00a0($8,181) was drawn down from the available credit of\u00a0\u00a0The operating line\u00a0of credit for \u00a0are secured by an interest in the inventory of CC Pharma GmbH as well as\u00a0the Densborn facility and underlying real property. The operating line of credit for is unsecured.
\n\u00a0
\nFour Twenty Corporation (\u201c420\u201d), a subsidiary of the Company, has a revolving credit facility of $30,000, which bears interest at SOFR plus an applicable margin. As of November 30, 2023, the Company has drawn $12,000 on the revolving line of credit. The revolving credit facility is secured by all of Montauk, the Craft Acquisition's assets\u00a0and 420's assets and includes a corporate guarantee by a subsidiary of the Company.\u00a0
\n\u00a0
\n "}]},{"name":"rpt:f-1065","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"us-gaap:PrimeRateMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-1066","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroShorttermRateMember"},"factValues":[{"value":"0.025","decimals":3}]},{"name":"rpt:f-1067","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroInterbankOfferedRateMember"},"factValues":[{"value":"0.04","decimals":2}]},{"name":"rpt:f-1068","factDimensions":{"xbrl:concept":"us-gaap:LineOfCredit","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"8181000","decimals":-3}]},{"name":"rpt:f-1069","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:FourTwentyCorporationMember","us-gaap:CreditFacilityAxis":"us-gaap:RevolvingCreditFacilityMember"},"factValues":[{"value":"30000000","decimals":-7}]},{"name":"rpt:f-1070","factDimensions":{"xbrl:concept":"us-gaap:LineOfCredit","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:FourTwentyCorporationMember","us-gaap:CreditFacilityAxis":"us-gaap:RevolvingCreditFacilityMember"},"factValues":[{"value":"12000000","decimals":-6}]},{"name":"rpt:f-1071","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 11. Accounts payable and accrued liabilities
\n\u00a0
\nAccounts payable and accrued liabilities are comprised of:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Trade payables | \n \u00a0 | \n$ | \n88,363 | \n\u00a0 | \n\u00a0 | \n$ | \n70,819 | \n\u00a0 | \n
| Accrued liabilities | \n \u00a0 | \n\u00a0 | \n75,851 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n48,394 | \n\u00a0 | \n
| Litigation expense accrual | \n \u00a0 | \n\u00a0 | \n25,338 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n25,000 | \n\u00a0 | \n
| Accrued payroll and employment related taxes | \n \u00a0 | \n\u00a0 | \n11,382 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,772 | \n\u00a0 | \n
| Income taxes payable | \n \u00a0 | \n\u00a0 | \n3,248 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n14,934 | \n\u00a0 | \n
| Accrued interest | \n \u00a0 | \n\u00a0 | \n8,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,102 | \n\u00a0 | \n
| Sales taxes payable | \n \u00a0 | \n\u00a0 | \n4,569 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,661 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n216,898 | \n\u00a0 | \n\u00a0 | \n$ | \n190,682 | \n\u00a0 | \n
\u00a0 \u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-1072","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n\u00a0 | \n2023 | \n\u00a0 | \n||
| Trade payables | \n \u00a0 | \n$ | \n88,363 | \n\u00a0 | \n\u00a0 | \n$ | \n70,819 | \n\u00a0 | \n
| Accrued liabilities | \n \u00a0 | \n\u00a0 | \n75,851 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n48,394 | \n\u00a0 | \n
| Litigation expense accrual | \n \u00a0 | \n\u00a0 | \n25,338 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n25,000 | \n\u00a0 | \n
| Accrued payroll and employment related taxes | \n \u00a0 | \n\u00a0 | \n11,382 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,772 | \n\u00a0 | \n
| Income taxes payable | \n \u00a0 | \n\u00a0 | \n3,248 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n14,934 | \n\u00a0 | \n
| Accrued interest | \n \u00a0 | \n\u00a0 | \n8,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,102 | \n\u00a0 | \n
| Sales taxes payable | \n \u00a0 | \n\u00a0 | \n4,569 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,661 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n216,898 | \n\u00a0 | \n\u00a0 | \n$ | \n190,682 | \n\u00a0 | \n
Note 12. Long-term debt
\n\u00a0
\nThe following table sets forth the net carrying amount of long-term debt instruments:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Credit facility - C$ - Canadian prime interest rate plus an applicable margin, -year term, with a -year amortization, repayable in blended monthly payments, due in | \u00a0 | $ | 42,920 | \u00a0 | \u00a0 | $ | 45,260 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 10,726 | \u00a0 | \u00a0 | \u00a0 | 10,959 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 12,937 | \u00a0 | \u00a0 | \u00a0 | 13,092 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 309 | \u00a0 | \u00a0 | \u00a0 | 346 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 2,125 | \u00a0 | \u00a0 | \u00a0 | 2,104 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 EURIBOR plus %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 112 | \u00a0 | \u00a0 | \u00a0 | 803 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 275 | \u00a0 | \u00a0 | \u00a0 | 755 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 634 | \u00a0 | \u00a0 | \u00a0 | 819 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 3,563 | \u00a0 | \u00a0 | \u00a0 | 1,706 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ including interest, due in | \u00a0 | \u00a0 | 20,512 | \u00a0 | \u00a0 | \u00a0 | 20,863 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 89,125 | \u00a0 | \u00a0 | \u00a0 | 65,000 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 183,238 | \u00a0 | \u00a0 | \u00a0 | 161,707 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (1,146 | ) | \u00a0 | \u00a0 | (738 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 182,092 | \u00a0 | \u00a0 | \u00a0 | 160,969 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (12,993 | ) | \u00a0 | \u00a0 | (24,080 | ) |
| Total noncurrent portion of long-term debt | \u00a0 | $ | 169,099 | \u00a0 | \u00a0 | $ | 136,889 | \u00a0 |
\u00a0
\nDuring the quarter ended August 31, 2023, Four Twenty Corporation (\"420\"), a wholly-owned subsidiary of the Company, repaid its $100,000 term loan and entered\u202f into a new secured credit agreement, which comprised of:\u202f(i) a $70,000 term loan facility, bearing interest at SOFR plus an applicable margin and having a maturity date of (the \"420 Term Loan\"), and (ii) a $20,000 delayed draw term loan facility, issued on the same terms as the $70,000 term loan facility (the \"420 Delayed Draw Term Loan\" and, together with the 420 Term Loan the \"420 Secured Credit Agreement\"). The 420 Term Loan was fully drawn on June 30, 2023. The 420 Delayed Draw Term Loan was fully drawn on September 29,\u00a02023 to fund part of the purchase price for the Craft\u00a0Acquisition\u00a0as described in Note 7 (Business acquisitions). Under the terms of the 420 Secured Credit Agreement, the Company pledged all of Sweetwater, Breckenridge, Montauk and the Craft Acquisition's\u00a0assets and the related equity interests, and Tilray Brands, Inc. provided a limited guarantee, as well as requiring the lenders approval to transfer assets to Tilray Brands, Inc.\u00a0
\n\u00a0
\nAs of November 30, 2023,\u00a0420 was not in compliance with the leverage ratio covenant under the 420 Secured Credit Agreement, but obtained a waiver from the lender on January 5, 2024.\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1090","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfDebtInstrumentsTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Credit facility - C$ - Canadian prime interest rate plus an applicable margin, -year term, with a -year amortization, repayable in blended monthly payments, due in | \u00a0 | $ | 42,920 | \u00a0 | \u00a0 | $ | 45,260 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 10,726 | \u00a0 | \u00a0 | \u00a0 | 10,959 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 12,937 | \u00a0 | \u00a0 | \u00a0 | 13,092 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 309 | \u00a0 | \u00a0 | \u00a0 | 346 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 2,125 | \u00a0 | \u00a0 | \u00a0 | 2,104 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 EURIBOR plus %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 112 | \u00a0 | \u00a0 | \u00a0 | 803 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 275 | \u00a0 | \u00a0 | \u00a0 | 755 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 634 | \u00a0 | \u00a0 | \u00a0 | 819 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 3,563 | \u00a0 | \u00a0 | \u00a0 | 1,706 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ including interest, due in | \u00a0 | \u00a0 | 20,512 | \u00a0 | \u00a0 | \u00a0 | 20,863 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 89,125 | \u00a0 | \u00a0 | \u00a0 | 65,000 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 183,238 | \u00a0 | \u00a0 | \u00a0 | 161,707 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (1,146 | ) | \u00a0 | \u00a0 | (738 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 182,092 | \u00a0 | \u00a0 | \u00a0 | 160,969 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (12,993 | ) | \u00a0 | \u00a0 | (24,080 | ) |
| Total noncurrent portion of long-term debt | \u00a0 | $ | 169,099 | \u00a0 | \u00a0 | $ | 136,889 | \u00a0 |
Note 13. Convertible debentures payable
\n\u00a0
\nThe following table sets forth the net carrying amount of the convertible debentures payable:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 123,691 | \u00a0 | \u00a0 | $ | 100,476 | \u00a0 |
| HTI Convertible Note | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | 47,834 | \u00a0 |
| % Convertible Notes (\"APHA 24\") | \u00a0 | \u00a0 | 128,399 | \u00a0 | \u00a0 | \u00a0 | 120,568 | \u00a0 |
| % Convertible Notes (\"TLRY 23\") | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | 126,544 | \u00a0 |
| Total | \u00a0 | \u00a0 | 252,090 | \u00a0 | \u00a0 | \u00a0 | 395,422 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | 128,399 | \u00a0 | \u00a0 | \u00a0 | 174,378 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 123,691 | \u00a0 | \u00a0 | $ | 221,044 | \u00a0 |
\u00a0
\nTLRY 27 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 150,000 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | (48,809 | ) | \u00a0 | \u00a0 | (49,524 | ) |
| Net carrying amount | \u00a0 | $ | 123,691 | \u00a0 | \u00a0 | $ | 100,476 | \u00a0 |
\u00a0
\nThe TLRY\u00a027\u00a0convertible debentures\u00a0were issued\u00a0on\u00a0 May 30, 2023 and on June 9, 2023 by way of overallotment,\u00a0in the principal amount of $172,500 (the \u201cTLRY 27 Notes\u201d). The TLRY 27 Notes\u00a0bear interest at a rate of\u00a05.20% per annum, payable semi-annually in arrears on\u00a0 June 15\u00a0and\u00a0 December 15\u00a0of each year, and mature on\u00a0 June 15, 2027,\u00a0unless earlier converted. The TLRY 27 Notes are Tilray\u2019s general unsecured obligations and rank senior in right of payment to all of Tilray\u2019s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray\u2019s unsecured indebtedness that is not so subordinated, including TLRY 23 and APHA 24, effectively junior in right of payment to any of Tilray\u2019s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray\u2019s current or future subsidiaries.\u00a0Noteholders will have the right to convert their TLRY\u00a027\u00a0Notes into shares of Tilray\u2019s common stock at their option, at any time, until the close of business on the\u00a0second\u00a0scheduled trading day immediately before\u00a0 June 15, 2027.\u00a0The initial conversion rate is\u00a0376.6478\u00a0shares per\u00a0$1,000\u00a0principal amount of TLRY\u00a027\u00a0Notes, which represents a conversion price of approximately\u00a0$2.66\u00a0per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.
\n\u00a0
\nThe TLRY\u00a027\u00a0Notes will be redeemable, in whole and\u00a0not\u00a0in part, at Tilray\u2019s option at any time on or after\u00a0\u00a0 June 20, 2025\u00a0at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price of Tilray\u2019s common stock exceeds\u00a0130% of the conversion price for a specified period of time. If certain corporate events that constitute a fundamental change occur, then, subject to a limited exception, noteholders\u00a0 may\u00a0require\u00a0Tilray\u00a0to repurchase their TLRY\u00a027\u00a0Notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. In connection with the Company\u2019s offering of the TLRY\u00a027\u00a0Notes, the Company entered into a share lending agreement with an affiliate of\u00a0Jefferies LLC\u00a0(the \u201cShare Borrower\u201d), pursuant to which it lent\u00a0to the Share Borrower\u00a038,500,000\u00a0shares of the Company\u2019s common stock (the \"Borrowed Shares\"). The Borrowed Shares were newly-issued shares,\u00a0will be held as treasury shares until the expiration or early termination of the share lending agreement\u00a0and may be used by purchasers of the TLRY\u00a027\u00a0Notes\u00a0to sell up to\u00a038,500,000\u00a0shares of the Company\u2019s common stock. The fair value of the share lending agreement has been recorded as part of the unamortized discount on the debenture. The Company expects that the selling stockholders will use their position created by such sales to establish their initial hedge with respect to their investments in the TLRY\u00a027\u00a0Notes. The Company did\u00a0not\u00a0receive any proceeds from the sale of the Borrowed Shares.\u00a0
\n\u00a0
\nDuring the three and six months ended November 30, 2023, the Company recognized interest expense of $2,423 and $4,485\u00a0and accretion of amortized discount interest of $2,829 and\u00a0$5,624. For the same periods in the prior year there was no interest or accretion of amortized discount.
\n\u00a0
\nHTI Convertible Note
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 50,000 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2,166 | ) |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 47,834 | \u00a0 |
\u00a0
\nOn July 12, 2022, the Company issued a $50,000 convertible promissory note to HTI (\"HTI Convertible Note\"), bearing a 4% interest rate\u00a0payable on a quarterly basis and having a maturity date of September 1, 2023. On August 31, 2023, the Company settled in full the HTI Convertible Note through the issuance of shares as described in Note 15\u00a0(Stockholders' equity).\u00a0\u00a0\u00a0\u00a0
\n\u00a0
\nAPHA 24 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 350,000 | \u00a0 | \u00a0 | $ | 350,000 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | (213,260 | ) | \u00a0 | \u00a0 | (213,260 | ) |
| Fair value adjustment | \u00a0 | \u00a0 | (8,341 | ) | \u00a0 | \u00a0 | (16,172 | ) |
| Net carrying amount | \u00a0 | $ | 128,399 | \u00a0 | \u00a0 | $ | 120,568 | \u00a0 |
\u00a0
\nThe APHA 24 convertible debentures, were entered into in April 2019, in the principal amount of $350,000, bear\u00a0interest at a rate of 5.25% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, and mature\u00a0on June 1, 2024, unless earlier converted (the APHA 24 Notes\"). The APHA 24 Notes\u00a0are Tilray\u2019s general unsecured obligations and rank senior in right of payment to all of Tilray\u2019s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray\u2019s unsecured indebtedness that is not so subordinated, including TLRY 23 and TLRY 27, effectively junior in right of payment to any of Tilray\u2019s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray\u2019s current or future subsidiaries.\u00a0
\n\u00a0
\nHolders of the APHA 24 Notes may convert all or any portion of such note, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date of June 1, 2024. The initial conversion which the Company may settle in cash, or common shares of Tilray, or a combination thereof, at Tilray's election,\u00a0is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events.\u00a0
\n\u00a0
\n \n \nThe Company\u00a0 may\u00a0redeem for cash all or part of the APHA\u00a024,\u00a0at its option, if the last reported sale price of the Company\u2019s common shares has been at least\u00a0130% of the conversion price then in effect for at least\u00a020\u00a0trading days during any\u00a030\u00a0consecutive trading day period ending on and including trading day immediately preceding the date on which the Company provides notice of redemption. The redemption of the APHA\u00a024\u00a0will be equal to\u00a0100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
\n\u00a0
\nThe Company elected the fair value option under ASC\u00a0825\u00a0Fair Value Measurements\u00a0for the APHA\u00a024.\u00a0The APHA\u00a024\u00a0was initially recognized at fair value on the balance sheet. All subsequent changes in fair value, excluding the impact of the change in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income (loss).
\n\u00a0
\nThe Company\u00a0plans to purchase or exchange some or all of its APHA\u00a024 Notes,\u00a0in open market purchases, privately negotiated transactions or otherwise prior to their maturity in June 2024. Such purchases or exchanges, if any, will depend on prevailing market conditions, contractual restrictions and other factors.\u00a0See\u00a0Note 27\u00a0(Subsequent Events)\u00a0for additional details.
\n\u00a0
\nThe overall change in fair value of APHA\u00a024\u00a0during the six months\u00a0ended\u00a0 November 30, 2023\u00a0decreased by $7,831 ( November 30, 2022\u00a0\u2013\u00a0$6,542 of fair value changes), this was comprised of $6,041 of fair value changes and a foreign exchange loss of $1,790.\u00a0
\n\u00a0
\nThere was $136,740\u00a0principal outstanding as at\u00a0 November 30, 2023\u00a0and May 31, 2023.
\n\u00a0
\nDuring the three and six months ended November 30, 2023,the Company recognized total interest expense of $1,795\u00a0and $3,589, respectively and\u00a0total interest expense of $3,393\u00a0and $6,786, respectively for the same period\u00a0in the prior year.
\n\u00a0
\nTLRY 23 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 277,856 | \u00a0 |
| Principal amount paid | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (150,526 | ) |
| Unamortized discount | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (786 | ) |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 126,544 | \u00a0 |
\u00a0
\nThe TLRY 23 Notes bore interest at a rate of 5.00% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. On\u00a0 September 12, 2023,\u00a0the Company repurchased $20,000\u00a0of its TLRY\u00a023\u00a0Notes for cancellation by issuing\u00a07,000,000\u00a0shares and paying $610\u00a0of cash to settle both principal and accrued interest. Upon repurchase of the TLRY 23 Notes, a portion of the\u00a0settlement consideration was allocated to the equity component of the instrument and\u00a0was\u00a0recognized as a $1,672 reduction of additional paid-in capital in the Consolidated Statements of Changes in Equity. Additionally, this repurchase resulted in a loss of $1,062\u00a0which was recorded in other non-operating (losses) gains, net as shown in Note\u00a024\u00a0(Non-operating income (expense)). \u00a0
\n\u00a0
\nAfter cancellation, the outstanding principal balance of the TLRY\u00a023\u00a0Notes was $107,330. On\u00a0 October 2, 2023,\u00a0the Company repaid the remaining principal\u00a0of the TLRY\u00a023\u00a0Notes in cash upon maturity.
\n\u00a0
\nDuring the three and six months ended November 30, 2023, the Company recognized total interest expense of $1,592 and $2,122, respectively and\u00a0total interest expense of $2,373\u00a0and $3,746, respectively for the same period\u00a0in the prior year.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1128","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebtTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 123,691 | \u00a0 | \u00a0 | $ | 100,476 | \u00a0 |
| HTI Convertible Note | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | 47,834 | \u00a0 |
| % Convertible Notes (\"APHA 24\") | \u00a0 | \u00a0 | 128,399 | \u00a0 | \u00a0 | \u00a0 | 120,568 | \u00a0 |
| % Convertible Notes (\"TLRY 23\") | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | 126,544 | \u00a0 |
| Total | \u00a0 | \u00a0 | 252,090 | \u00a0 | \u00a0 | \u00a0 | 395,422 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | 128,399 | \u00a0 | \u00a0 | \u00a0 | 174,378 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 123,691 | \u00a0 | \u00a0 | $ | 221,044 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 150,000 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | (48,809 | ) | \u00a0 | \u00a0 | (49,524 | ) |
| Net carrying amount | \u00a0 | $ | 123,691 | \u00a0 | \u00a0 | $ | 100,476 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 50,000 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2,166 | ) |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 47,834 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 350,000 | \u00a0 | \u00a0 | $ | 350,000 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | (213,260 | ) | \u00a0 | \u00a0 | (213,260 | ) |
| Fair value adjustment | \u00a0 | \u00a0 | (8,341 | ) | \u00a0 | \u00a0 | (16,172 | ) |
| Net carrying amount | \u00a0 | $ | 128,399 | \u00a0 | \u00a0 | $ | 120,568 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 277,856 | \u00a0 |
| Principal amount paid | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (150,526 | ) |
| Unamortized discount | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (786 | ) |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 126,544 | \u00a0 |
Note 14. Warrant liability
\n\u00a0
\nAs of November 30, 2023 and May 31, 2023, there were 6,209,000 warrants outstanding, with an original exercise price of $5.95 per warrant, expiring March 17, 2025. Each warrant is exercisable for one common share of the Company.
\n\u00a0
\nThe warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the six months ended November 30, 2023, the Company issued shares which triggered the anti-dilution price protection feature lowering the exercise price to $1.61. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of common stock due to be issued multiplied by any trading price of the common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.
\n\u00a0
\nThe Company estimated the fair value of warrants outstanding at November 30, 2023 at $0.607\u00a0per warrant using the Black Scholes pricing model (Level 3) with the following assumptions: Risk-free interest rate of 4.4%, expected volatility of 50%, expected term of 1.30\u00a0years, strike price of $1.61\u00a0and fair value of common stock of $1.81.
\n\u00a0
\nExpected volatility is based on both historical and implied volatility of the Company\u2019s common stock.
\n "}]},{"name":"rpt:f-1213","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"6209000"}]},{"name":"rpt:f-1214","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares"},"factValues":[{"value":"5.95"}]},{"name":"rpt:f-1215","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"1"}]},{"name":"rpt:f-1216","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"1.61"}]},{"name":"rpt:f-1217","factDimensions":{"xbrl:concept":"tlry:PercentageOfDailyCashPenalty","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"0.01","decimals":2}]},{"name":"rpt:f-1218","factDimensions":{"xbrl:concept":"tlry:EstimatedFairValueOfWarrantLiabilityPerWarrant","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member"},"factValues":[{"value":"0.607"}]},{"name":"rpt:f-1219","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputRiskFreeInterestRateMember"},"factValues":[{"value":"0.044","decimals":3}]},{"name":"rpt:f-1220","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputPriceVolatilityMember"},"factValues":[{"value":"0.50","decimals":1}]},{"name":"rpt:f-1221","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputExpectedTermMember"},"factValues":[{"value":"1.3"}]},{"name":"rpt:f-1222","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputConversionPriceMember"},"factValues":[{"value":"1.61"}]},{"name":"rpt:f-1223","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputSharePriceMember"},"factValues":[{"value":"1.81"}]},{"name":"rpt:f-1224","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 15. Stockholders' equity\u00a0
\n\u00a0
\nIssued and outstanding
\n\u00a0
\nAs of\u00a0\u00a0 November 30, 2023, the Company had 1,198,000,000\u00a0common shares and 10,000,000 preferred shares authorized to be issued, with\u00a0732,907,552 common shares and preferred shares issued and outstanding. Historically, the Company has issued shares of its common stock as consideration for business acquisitions, including the settlement of convertible notes, the settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.
\n\u00a0
\nDuring the six months ended November 30, 2023, the Company issued the following common\u00a0shares:
\n\u00a0
\n| \u00a0 | a) | \n 39,705,962\u00a0shares in connection with the HEXO Acquisition, see Note 7 (Business acquisitions). |
| \u00a0 | b) | 865,426\u00a0shares to settle a contractual change of\u00a0control severance obligations in the aggregate amount of $1,500\u00a0incurred in connection with the HEXO Acquisition. |
| \u00a0 | c) | 5,004,735\u00a0shares to settle dividends payable to the non-controlling shareholders of Aphria Diamond in the amount of $8,146.\u00a0 |
| \u00a0 | d) | 17,148,541\u00a0shares for the settlement of the HTI Convertible Note payable see Note\u00a013\u00a0(Convertible debentures payable). |
| \u00a0 | e) | 1,032,616\u00a0shares to HTI Investments MA LLC pursuant to the terms of a $50.0 million convertible promissory note originally issued by Tilray to HTI on July 12, 2022 and which was settled at maturity as previously disclosed. |
| \u00a0 | f) | 1,573,152\u00a0shares to settle HEXO-based litigation judgement obtained by MediPharm Labs Inc. in 2022. |
| \u00a0 | g) | 7,000,000\u00a0shares to repurchase\u00a0$20,000 of its TLRY 23 Notes for cancellation. |
| \u00a0 | h) | 3,921,665\u00a0shares in connection with the exercise of previously awarded stock-based compensation awards. |
\u00a0
\nThe Company maintains stock-based compensation plans as disclosed in our Annual Financial Statements. For the three and six months ended November 30, 2023,\u00a0the total stock-based compensation was $ 8,201 and $ 16,458. For the\u00a0three\u00a0and\u00a0six\u00a0months ended\u00a0\u00a0 November 30, 2022, total stock based compensation was $ 10,943\u00a0and\u00a0$ 20,136 respectively.
\u00a0
During the six months ended November 30, 2023\u00a0the Company granted 11,559,549 time-based RSUs,\u00a0and 7,566,146 performance-based RSUs ( November 30, 2022 - 6,004,995 time-based RSUs and 2,634,744 performance based RSUs).\u00a0The 7,566,146 performance based RSUs issued during the quarter had performance conditions not yet finalized.\u00a0The Company's total stock-based compensation expense recognized is as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Stock options | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 20 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 624 | \u00a0 |
| RSUs | \u00a0 | \u00a0 | 8,201 | \u00a0 | \u00a0 | \u00a0 | 10,923 | \u00a0 | \u00a0 | \u00a0 | 16,458 | \u00a0 | \u00a0 | \u00a0 | 19,512 | \u00a0 |
| Total | \u00a0 | $ | 8,201 | \u00a0 | \u00a0 | $ | 10,943 | \u00a0 | \u00a0 | $ | 16,458 | \u00a0 | \u00a0 | $ | 20,136 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-1225","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"1198000000"}]},{"name":"rpt:f-1226","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesAuthorized","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"10000000"}]},{"name":"rpt:f-1227","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesIssued","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"732907552"}]},{"name":"rpt:f-1228","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AssetAcquisitionAxis":"tlry:HexoMember"},"factValues":[{"value":"39705962"}]},{"name":"rpt:f-1229","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesSettlementOfFinancingLiability","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AssetAcquisitionAxis":"tlry:HexoMember"},"factValues":[{"value":"865426"}]},{"name":"rpt:f-1230","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodValueSettlementOfFinancingLiability","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"tlry:HexoMember"},"factValues":[{"value":"1500000","decimals":-5}]},{"name":"rpt:f-1231","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesSettlementOfDividendPayable","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","srt:CounterpartyNameAxis":"tlry:AphriaDiamondMember"},"factValues":[{"value":"5004735"}]},{"name":"rpt:f-1232","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodValueSettlementOfDividendPayable","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:CounterpartyNameAxis":"tlry:AphriaDiamondMember"},"factValues":[{"value":"8146000","decimals":-3}]},{"name":"rpt:f-1233","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesSettlementOfConvertibleSecurities","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"tlry:HTIConvertibleNotePayableMember"},"factValues":[{"value":"17148541"}]},{"name":"rpt:f-1234","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesForDerivativeSettlementDownsideProtection","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtConversionByUniqueDescriptionAxis":"tlry:DerivativeSettlementMember","us-gaap:DebtInstrumentAxis":"tlry:HTInvestmentsMALLCNoteMember"},"factValues":[{"value":"1032616"}]},{"name":"rpt:f-1235","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfConvertibleDebt","xbrl:period":"2022-07-12T00:00:00/2022-07-13T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:HTIConvertibleNotePayableMember"},"factValues":[{"value":"50000000","decimals":-7}]},{"name":"rpt:f-1236","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesLegalSettlement","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMember"},"factValues":[{"value":"1573152"}]},{"name":"rpt:f-1237","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesForTheRepaymentOfConvertibleDebt","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"tlry:TLRY23Member"},"factValues":[{"value":"7000000"}]},{"name":"rpt:f-1238","factDimensions":{"xbrl:concept":"tlry:ConvertibleDebtInstrumentRepurchaseAmount","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:TLRY23Member"},"factValues":[{"value":"20000000","decimals":-7}]},{"name":"rpt:f-1239","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"3921665"}]},{"name":"rpt:f-1240","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"8201000","decimals":-3}]},{"name":"rpt:f-1241","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"16458000","decimals":-3}]},{"name":"rpt:f-1242","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"10943000","decimals":-3}]},{"name":"rpt:f-1243","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"20136000","decimals":-3}]},{"name":"rpt:f-1244","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:TimebasedRestrictedStockUnitsMember"},"factValues":[{"value":"11559549"}]},{"name":"rpt:f-1245","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"7566146"}]},{"name":"rpt:f-1246","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2022-11-30T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:TimebasedRestrictedStockUnitsMember"},"factValues":[{"value":"6004995"}]},{"name":"rpt:f-1247","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2022-11-30T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"2634744"}]},{"name":"rpt:f-1248","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"7566146"}]},{"name":"rpt:f-1249","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Stock options | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 20 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 624 | \u00a0 |
| RSUs | \u00a0 | \u00a0 | 8,201 | \u00a0 | \u00a0 | \u00a0 | 10,923 | \u00a0 | \u00a0 | \u00a0 | 16,458 | \u00a0 | \u00a0 | \u00a0 | 19,512 | \u00a0 |
| Total | \u00a0 | $ | 8,201 | \u00a0 | \u00a0 | $ | 10,943 | \u00a0 | \u00a0 | $ | 16,458 | \u00a0 | \u00a0 | $ | 20,136 | \u00a0 |
Note 16. Accumulated other comprehensive income (loss)
\n\u00a0
\nAccumulated other comprehensive loss includes the following components:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n Unrealized | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n|
| \u00a0 | \n\u00a0 | \n Foreign | \n \u00a0 | \n\u00a0 | \n loss on | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n currency | \n \u00a0 | \n\u00a0 | \n convertible | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n translation | \n \u00a0 | \n\u00a0 | \n notes | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n gain (loss) | \n \u00a0 | \n\u00a0 | \n receivables | \n \u00a0 | \n\u00a0 | \n Total | \n \u00a0 | \n|||
| Balance May 31, 2022 | \n \u00a0 | \n$ | \n54,413 | \n\u00a0 | \n\u00a0 | \n$ | \n(75,177 | \n) | \n\u00a0 | \n\u00a0 | \n(20,764 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n(56,443 | \n) | \n\u00a0 | \n\u00a0 | \n(2,525 | \n) | \n\u00a0 | \n\u00a0 | \n(58,968 | \n) | \n
| Balance August 31, 2022 | \n \u00a0 | \n$ | \n(2,030 | \n) | \n\u00a0 | \n$ | \n(77,702 | \n) | \n\u00a0 | \n$ | \n(79,732 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n(24,080 | \n) | \n\u00a0 | \n\u00a0 | \n(17,643 | \n) | \n\u00a0 | \n\u00a0 | \n(41,723 | \n) | \n
| Balance at November 30, 2022 | \n \u00a0 | \n$ | \n(26,110 | \n) | \n\u00a0 | \n$ | \n(95,345 | \n) | \n\u00a0 | \n$ | \n(121,455 | \n) | \n
| \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Balance May 31, 2023 | \n \u00a0 | \n$ | \n(46,610 | \n) | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n\u00a0 | \n$ | \n(46,610 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n3,049 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n3,049 | \n\u00a0 | \n
| Balance August 31, 2023 | \n \u00a0 | \n$ | \n(43,561 | \n) | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n\u00a0 | \n$ | \n(43,561 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n5,194 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,194 | \n\u00a0 | \n
| Balance November 30, 2023 | \n \u00a0 | \n$ | \n(38,367 | \n) | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n\u00a0 | \n$ | \n(38,367 | \n) | \n
\u00a0
\n "}]},{"name":"rpt:f-1263","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n Unrealized | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n|
| \u00a0 | \n\u00a0 | \n Foreign | \n \u00a0 | \n\u00a0 | \n loss on | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n currency | \n \u00a0 | \n\u00a0 | \n convertible | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n translation | \n \u00a0 | \n\u00a0 | \n notes | \n \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n gain (loss) | \n \u00a0 | \n\u00a0 | \n receivables | \n \u00a0 | \n\u00a0 | \n Total | \n \u00a0 | \n|||
| Balance May 31, 2022 | \n \u00a0 | \n$ | \n54,413 | \n\u00a0 | \n\u00a0 | \n$ | \n(75,177 | \n) | \n\u00a0 | \n\u00a0 | \n(20,764 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n(56,443 | \n) | \n\u00a0 | \n\u00a0 | \n(2,525 | \n) | \n\u00a0 | \n\u00a0 | \n(58,968 | \n) | \n
| Balance August 31, 2022 | \n \u00a0 | \n$ | \n(2,030 | \n) | \n\u00a0 | \n$ | \n(77,702 | \n) | \n\u00a0 | \n$ | \n(79,732 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n(24,080 | \n) | \n\u00a0 | \n\u00a0 | \n(17,643 | \n) | \n\u00a0 | \n\u00a0 | \n(41,723 | \n) | \n
| Balance at November 30, 2022 | \n \u00a0 | \n$ | \n(26,110 | \n) | \n\u00a0 | \n$ | \n(95,345 | \n) | \n\u00a0 | \n$ | \n(121,455 | \n) | \n
| \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Balance May 31, 2023 | \n \u00a0 | \n$ | \n(46,610 | \n) | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n\u00a0 | \n$ | \n(46,610 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n3,049 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n3,049 | \n\u00a0 | \n
| Balance August 31, 2023 | \n \u00a0 | \n$ | \n(43,561 | \n) | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n\u00a0 | \n$ | \n(43,561 | \n) | \n
| Other comprehensive loss | \n \u00a0 | \n\u00a0 | \n5,194 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u2014 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,194 | \n\u00a0 | \n
| Balance November 30, 2023 | \n \u00a0 | \n$ | \n(38,367 | \n) | \n\u00a0 | \n$ | \n\u2014 | \n\u00a0 | \n\u00a0 | \n$ | \n(38,367 | \n) | \n
Note 17. Non-controlling interests
\n\u00a0
\nThe following tables summarize the information relating to the Company\u2019s subsidiaries, SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and ColCanna S.A.S. (90%) before intercompany eliminations.\u00a0
\n\u00a0
\nSummary of balance sheet information of the entities in which there is a non-controlling interest as of November 30, 2023:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 73 | \u00a0 | \u00a0 | $ | 131,023 | \u00a0 | \u00a0 | $ | 196 | \u00a0 | \u00a0 | $ | 131,292 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 131,726 | \u00a0 | \u00a0 | \u00a0 | 3,580 | \u00a0 | \u00a0 | \u00a0 | 209,987 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (14 | ) | \u00a0 | \u00a0 | (129,105 | ) | \u00a0 | \u00a0 | (6,613 | ) | \u00a0 | \u00a0 | (135,732 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,195 | ) | \u00a0 | \u00a0 | (49,833 | ) | \u00a0 | \u00a0 | (1,460 | ) | \u00a0 | \u00a0 | (52,488 | ) |
| Net assets | \u00a0 | $ | 74,681 | \u00a0 | \u00a0 | $ | (1,136 | ) | \u00a0 | $ | 83,811 | \u00a0 | \u00a0 | $ | (4,297 | ) | \u00a0 | $ | 153,059 | \u00a0 |
\u00a0
\nSummary of balance sheet information of the entities there is a non-controlling interest\u00a0as of May 31, 2023:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 114 | \u00a0 | \u00a0 | $ | 127,689 | \u00a0 | \u00a0 | $ | 224 | \u00a0 | \u00a0 | $ | 128,027 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 135,085 | \u00a0 | \u00a0 | \u00a0 | 3,307 | \u00a0 | \u00a0 | \u00a0 | 213,073 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,166 | ) | \u00a0 | \u00a0 | (142,554 | ) | \u00a0 | \u00a0 | (6,697 | ) | \u00a0 | \u00a0 | (150,417 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (53,197 | ) | \u00a0 | \u00a0 | (1,428 | ) | \u00a0 | \u00a0 | (54,625 | ) |
| Net assets | \u00a0 | $ | 74,681 | \u00a0 | \u00a0 | $ | (1,052 | ) | \u00a0 | $ | 67,023 | \u00a0 | \u00a0 | $ | (4,594 | ) | \u00a0 | $ | 136,058 | \u00a0 |
\u00a0
\n \n \nSummary of income statement information of the entities in which there is a non-controlling interest\u00a0for the six months ended November 30, 2023:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 54 | \u00a0 | \u00a0 | \u00a0 | 32,803 | \u00a0 | \u00a0 | \u00a0 | (519 | ) | \u00a0 | \u00a0 | 32,338 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (54 | ) | \u00a0 | \u00a0 | 24,275 | \u00a0 | \u00a0 | \u00a0 | 519 | \u00a0 | \u00a0 | \u00a0 | 24,740 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (30 | ) | \u00a0 | \u00a0 | 404 | \u00a0 | \u00a0 | \u00a0 | (222 | ) | \u00a0 | \u00a0 | 152 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (84 | ) | \u00a0 | $ | 24,679 | \u00a0 | \u00a0 | $ | 297 | \u00a0 | \u00a0 | $ | 24,892 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | (21 | ) | \u00a0 | \u00a0 | 12,093 | \u00a0 | \u00a0 | \u00a0 | 30 | \u00a0 | \u00a0 | \u00a0 | 12,102 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (21 | ) | \u00a0 | $ | 18,647 | \u00a0 | \u00a0 | $ | 30 | \u00a0 | \u00a0 | $ | 18,656 | \u00a0 |
\u00a0
\nSummary of income statement information of the entities in which there is a non-controlling interest\u00a0for the six months ended November 30, 2022:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2022 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 108 | \u00a0 | \u00a0 | $ | 65,437 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 65,545 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | (7,006 | ) | \u00a0 | \u00a0 | 471 | \u00a0 | \u00a0 | \u00a0 | 39,039 | \u00a0 | \u00a0 | \u00a0 | 56,265 | \u00a0 | \u00a0 | \u00a0 | 88,769 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | 7,006 | \u00a0 | \u00a0 | \u00a0 | (363 | ) | \u00a0 | \u00a0 | 26,398 | \u00a0 | \u00a0 | \u00a0 | (56,265 | ) | \u00a0 | \u00a0 | (23,224 | ) |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | (11,321 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,590 | ) | \u00a0 | \u00a0 | 363 | \u00a0 | \u00a0 | \u00a0 | (12,548 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | (4,315 | ) | \u00a0 | $ | (363 | ) | \u00a0 | $ | 24,808 | \u00a0 | \u00a0 | $ | (55,902 | ) | \u00a0 | $ | (35,772 | ) |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | (1,381 | ) | \u00a0 | \u00a0 | (91 | ) | \u00a0 | \u00a0 | 12,156 | \u00a0 | \u00a0 | \u00a0 | (5,590 | ) | \u00a0 | \u00a0 | 5,094 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,056 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,056 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | (1,381 | ) | \u00a0 | $ | (91 | ) | \u00a0 | $ | 18,212 | \u00a0 | \u00a0 | $ | (5,590 | ) | \u00a0 | $ | 11,150 | \u00a0 |
\u00a0 \u00a0 \u00a0\u00a0
\nOn January 5, 2024, Aphria Inc. (\u201cAphria\u201d), a wholly-owned subsidiary of the Company, entered into an Amended and Restated Wholesale Cannabis Supply Agreement (the \u201cSupply Agreement\u201d) with 1974568 Ontario Limited (\u201cAphria Diamond\u201d), Aphria\u2019s joint venture with Double Diamond Holdings Ltd. The Supply Agreement amends and restates the existing supply agreement, effective as of September 1, 2023, and amends certain terms relating to pricing and product classes.\u00a0Due to the terms stipulated in the Supply Agreement, the reduced transfer price will lead to a decrease in income attributable to non-controlling interest over the duration of the agreement. If this agreement had been effective June 1, 2023, the Company would have recognized approximately $15,000 in additional net income attributed to the Stockholders of Tilray Brands, Inc.
\n "}]},{"name":"rpt:f-1295","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:SuperheroAcquisitionLPMember"},"factValues":[{"value":"0.68","decimals":2}]},{"name":"rpt:f-1296","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:CCPharmaNordicApSMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-1297","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:AphriaDiamondMember"},"factValues":[{"value":"0.51","decimals":2}]},{"name":"rpt:f-1298","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:ColCannaSASMember"},"factValues":[{"value":"0.90","decimals":1}]},{"name":"rpt:f-1299","factDimensions":{"xbrl:concept":"srt:ScheduleOfCondensedBalanceSheetTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 73 | \u00a0 | \u00a0 | $ | 131,023 | \u00a0 | \u00a0 | $ | 196 | \u00a0 | \u00a0 | $ | 131,292 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 131,726 | \u00a0 | \u00a0 | \u00a0 | 3,580 | \u00a0 | \u00a0 | \u00a0 | 209,987 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (14 | ) | \u00a0 | \u00a0 | (129,105 | ) | \u00a0 | \u00a0 | (6,613 | ) | \u00a0 | \u00a0 | (135,732 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,195 | ) | \u00a0 | \u00a0 | (49,833 | ) | \u00a0 | \u00a0 | (1,460 | ) | \u00a0 | \u00a0 | (52,488 | ) |
| Net assets | \u00a0 | $ | 74,681 | \u00a0 | \u00a0 | $ | (1,136 | ) | \u00a0 | $ | 83,811 | \u00a0 | \u00a0 | $ | (4,297 | ) | \u00a0 | $ | 153,059 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 114 | \u00a0 | \u00a0 | $ | 127,689 | \u00a0 | \u00a0 | $ | 224 | \u00a0 | \u00a0 | $ | 128,027 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 135,085 | \u00a0 | \u00a0 | \u00a0 | 3,307 | \u00a0 | \u00a0 | \u00a0 | 213,073 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,166 | ) | \u00a0 | \u00a0 | (142,554 | ) | \u00a0 | \u00a0 | (6,697 | ) | \u00a0 | \u00a0 | (150,417 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (53,197 | ) | \u00a0 | \u00a0 | (1,428 | ) | \u00a0 | \u00a0 | (54,625 | ) |
| Net assets | \u00a0 | $ | 74,681 | \u00a0 | \u00a0 | $ | (1,052 | ) | \u00a0 | $ | 67,023 | \u00a0 | \u00a0 | $ | (4,594 | ) | \u00a0 | $ | 136,058 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 54 | \u00a0 | \u00a0 | \u00a0 | 32,803 | \u00a0 | \u00a0 | \u00a0 | (519 | ) | \u00a0 | \u00a0 | 32,338 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (54 | ) | \u00a0 | \u00a0 | 24,275 | \u00a0 | \u00a0 | \u00a0 | 519 | \u00a0 | \u00a0 | \u00a0 | 24,740 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (30 | ) | \u00a0 | \u00a0 | 404 | \u00a0 | \u00a0 | \u00a0 | (222 | ) | \u00a0 | \u00a0 | 152 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (84 | ) | \u00a0 | $ | 24,679 | \u00a0 | \u00a0 | $ | 297 | \u00a0 | \u00a0 | $ | 24,892 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | - | \u00a0 | \u00a0 | \u00a0 | (21 | ) | \u00a0 | \u00a0 | 12,093 | \u00a0 | \u00a0 | \u00a0 | 30 | \u00a0 | \u00a0 | \u00a0 | 12,102 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (21 | ) | \u00a0 | $ | 18,647 | \u00a0 | \u00a0 | $ | 30 | \u00a0 | \u00a0 | $ | 18,656 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2022 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 108 | \u00a0 | \u00a0 | $ | 65,437 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 65,545 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | (7,006 | ) | \u00a0 | \u00a0 | 471 | \u00a0 | \u00a0 | \u00a0 | 39,039 | \u00a0 | \u00a0 | \u00a0 | 56,265 | \u00a0 | \u00a0 | \u00a0 | 88,769 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | 7,006 | \u00a0 | \u00a0 | \u00a0 | (363 | ) | \u00a0 | \u00a0 | 26,398 | \u00a0 | \u00a0 | \u00a0 | (56,265 | ) | \u00a0 | \u00a0 | (23,224 | ) |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | (11,321 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,590 | ) | \u00a0 | \u00a0 | 363 | \u00a0 | \u00a0 | \u00a0 | (12,548 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | (4,315 | ) | \u00a0 | $ | (363 | ) | \u00a0 | $ | 24,808 | \u00a0 | \u00a0 | $ | (55,902 | ) | \u00a0 | $ | (35,772 | ) |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | (1,381 | ) | \u00a0 | \u00a0 | (91 | ) | \u00a0 | \u00a0 | 12,156 | \u00a0 | \u00a0 | \u00a0 | (5,590 | ) | \u00a0 | \u00a0 | 5,094 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,056 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,056 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | (1,381 | ) | \u00a0 | $ | (91 | ) | \u00a0 | $ | 18,212 | \u00a0 | \u00a0 | $ | (5,590 | ) | \u00a0 | $ | 11,150 | \u00a0 |
Note 18. Income taxes
\n\u00a0
\nThe determination of the Company\u2019s overall effective\u00a0tax\u00a0rate requires significant judgment, the use of estimates, and the interpretation and application of complex\u00a0tax\u00a0laws. The effective\u00a0tax\u00a0rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions.\u00a0Tax\u00a0law changes, increases, and decreases in temporary and permanent differences between book and\u00a0tax\u00a0items, valuation allowances against the deferred tax assets, stock compensation, and the Company\u2019s change in income in each jurisdiction all affect the overall effective\u00a0tax\u00a0rate. It is the Company\u2019s practice to recognize interest and penalties related to uncertain\u00a0tax\u00a0positions in income\u00a0tax\u00a0expense.
\n\u00a0
\nThe Company reported income tax (recovery) expense of $(3,380)\u00a0and $3,884 for the three and six months ended November 30, 2023, and\u00a0income tax recovery of $(11,713)\u00a0and $ (4,502)\u00a0for the three and six months ended November 30, 2022.\u00a0The income tax benefit\u00a0in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1441","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3380000","decimals":-4}]},{"name":"rpt:f-1442","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-3884000","decimals":-3}]},{"name":"rpt:f-1443","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"11713000","decimals":-3}]},{"name":"rpt:f-1444","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4502000","decimals":-3}]},{"name":"rpt:f-1445","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 19. Commitments and contingencies
\n\u00a0
\nPurchase and other commitments
\n\u00a0
\nThe Company has payments on long-term debt, refer to Note 12\u00a0(Long-term debt), convertible notes, refer to Note 13\u00a0(Convertible debentures payable), material purchase commitments and construction commitments as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 183,238 | \u00a0 | \u00a0 | $ | 12,993 | \u00a0 | \u00a0 | $ | 45,968 | \u00a0 | \u00a0 | $ | 8,953 | \u00a0 | \u00a0 | $ | 10,332 | \u00a0 | \u00a0 | $ | 104,992 | \u00a0 |
| Convertible notes | \u00a0 | \u00a0 | 309,240 | \u00a0 | \u00a0 | \u00a0 | 136,740 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 172,500 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 56,972 | \u00a0 | \u00a0 | \u00a0 | 33,584 | \u00a0 | \u00a0 | \u00a0 | 21,388 | \u00a0 | \u00a0 | \u00a0 | 2,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Construction commitments | \u00a0 | \u00a0 | 822 | \u00a0 | \u00a0 | \u00a0 | 822 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 550,272 | \u00a0 | \u00a0 | $ | 184,139 | \u00a0 | \u00a0 | $ | 67,356 | \u00a0 | \u00a0 | $ | 10,953 | \u00a0 | \u00a0 | $ | 182,832 | \u00a0 | \u00a0 | $ | 104,992 | \u00a0 |
\u00a0
\nLegal proceedings
\n\u00a0
\nIn the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves\u00a0 may\u00a0be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is\u00a0not\u00a0probable or the amount of loss is\u00a0not\u00a0estimable, we do\u00a0not\u00a0accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are\u00a0not\u00a0expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable,\u00a0 may\u00a0be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.
\n\u00a0
\nThere have been no material changes from the legal proceedings since\u00a0our Annual Report on Form 10-K\u00a0for the fiscal year ended May 31, 2023, except with respect to certain aspects of the legal proceedings disclosed below:
\n\u00a0
\nClass Action Suits and Stockholder Derivative Suits
\n\u00a0
\nAuthentic Brands Group Related Class Action\u00a0(New York, United States)
\n\u00a0
\nOn\u00a0 May 4, 2020,\u00a0Ganesh Kasilingam filed a lawsuit in the United States District Court for the Southern District of New York (\u201cSDNY\u201d), against Tilray Brands, Inc., Brendan Kennedy and Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections\u00a010(b) and\u00a020(a) of the Securities Exchange Act of\u00a01934\u00a0(the \u201cKasilingam litigation\u201d). The complaint alleges that Tilray and the individual defendants overstated the anticipated advantages of the Company\u2019s revenue sharing agreement with Authentic Brands Group (\u201cABG\u201d), announced on\u00a0 January 15, 2019,\u00a0and that the plaintiff suffered losses when Tilray\u2019s stock price dropped after Tilray recognized an impairment with respect to the ABG deal on\u00a0 March 2, 2020.\u00a0On\u00a0 August 6, 2020,\u00a0SDNY entered an order appointing Saul Kassin as Lead Plaintiff and The Rosen Law Firm, P.A. as Lead Counsel. Lead Plaintiff filed an amended complaint on\u00a0 October 5, 2020,\u00a0which asserts the same Sections\u00a010(b) and\u00a020(a) claims against the same defendants on largely the same theory, and includes new allegations that Tilray\u2019s reported inventory, cost of sales, and gross margins in its financial reports during the class period were false and misleading because Tilray improperly recorded unsellable \u201ctrim\u201d as inventory and understated the cost of sales for its products.
\n\u00a0
\nOn\u00a0 September 27, 2021,\u00a0the U.S. District Court entered an Opinion & Order granting the Defendants\u2019 motion to dismiss the amended complaint in the Kasilingam litigation without prejudice. On\u00a0 December 3, 2021,\u00a0the lead plaintiff filed a\u00a0second\u00a0amended complaint alleging similar claims against Tilray and Brendan Kennedy. The defendants moved to dismiss the second amended complaint on\u00a0 February 2, 2022.\u00a0On\u00a0 September 28, 2022,\u00a0the Court granted in part and denied in part the defendants\u2019 motion to dismiss the\u00a0second\u00a0amended complaint. On\u00a0 October 12, 2022,\u00a0the Company filed a motion for reconsideration and/or interlocutory appeal of this Court decision.
\n\u00a0
\nOn August 21, 2023, the U.S. District Court granted Tilray\u2019s motion for reconsideration and dismissed the second amended complaint with leave to amend one final time. On September 27, 2023, plaintiff filed a third amended complaint. Tilray continues to believe that all of the underlying claims in the amended complaint are without merit\u00a0and should be dismissed with prejudice.
\n\u00a0
\n \n \nLegal Proceedings Related to Contractual Obligations
\n\u00a0
\n420\u00a0Investments Ltd. Litigation
\n\u00a0
\nOn\u00a0 February 21, 2020,\u00a0420\u00a0Investments Ltd., as Plaintiff (\u201c420\u00a0Investments\u201d), filed a lawsuit against Tilray Brands, Inc. and High Park Shops Inc. as Defendants, in Calgary, Alberta in the Court of Queen\u2019s Bench of Alberta. In\u00a0 August 2019,\u00a0Tilray and High Park entered into an Arrangement Agreement with\u00a0420\u00a0Investments and others (the \u201cAgreement\u201d). Pursuant to the Agreement, High Park was to acquire the securities of\u00a0420\u00a0Investments. In\u00a0 February 2020,\u00a0Tilray and High Park gave notice of termination of the Agreement.\u00a0420\u00a0Investments alleges that the termination was unlawful and without merit and further alleges that the Defendants had\u00a0no\u00a0legal basis to terminate.\u00a0420\u00a0Investments alleges that the Defendants did\u00a0not\u00a0meet their contractual and good faith obligations under the Agreement.\u00a0420\u00a0Investment seeks damages in the stated amount of\u00a0\u00a0plus\u00a0\u00a0in aggravated damages. The Tilray and High Park Statement of Defense and counterclaim were both filed on\u00a0 March 20, 2020.\u00a0420\u00a0Investment\u2019s Statement of Defense to our counterclaim was filed on\u00a0 April 20, 2020.\u00a0Respectively,\u00a0420\u00a0Investments and Tilray / High Park served each other with their Affidavits of Records on\u00a0 August 25, 2020\u00a0and\u00a0 November 30, 2020.\u00a0Tilray and High Park cross-examined the litigation representative of\u00a0420\u00a0Investments. The Company denies the Plaintiff\u2019s allegations and intends to continue to vigorously defend this litigation matter, although there can be\u00a0no\u00a0assurance as to its outcome.
\n\u00a0
\nIn\u00a0 February 2023,\u00a0Tilray and High Park filed an Application for Summary Judgment to collect an unpaid\u00a0\u00a0bridge loan made to\u00a0420\u00a0Investments on\u00a0 August 28, 2019,\u00a0relating to the subject transaction.\u00a0 That debt was repayable in\u00a0 March 2020,\u00a0but was never repaid.\u00a0 The application is pending and a decision from the Court is expected on Tilray\u2019s Application for Summary Judgment in the calendar year of 2024.
\n\u00a0
\nDocklight Litigation Settlement
\n\u00a0
\nOn\u00a0 November 5, 2021\u00a0Docklight Brands, Inc. (\u201cDocklight\u201d) filed a complaint against the Company and its wholly-owned subsidiary, High Park Holdings, Ltd. in Superior Court of the State of Washington, King County. Docklight claimed breach of contract against High Park arising from a\u00a02018\u00a0license agreement pursuant to which Docklight licensed certain Bob Marley-related brands to High Park (as amended in\u00a02020\u00a0and\u00a02021,\u00a0the \u201cHigh Park License\u201d). In addition, Docklight brought a negligent misrepresentation claim against Tilray, alleging that certain individuals at Tilray or Aphria had made false statements to Docklight in order to induce Docklight to waive Docklight\u2019s alleged right to terminate the High Park License for change-of-control on the basis of the\u00a02021\u00a0Tilray-Aphria Arrangement Agreement. Effective October 10, 2023, the parties entered into a settlement agreement pursuant to which the Company paid an aggregate amount equal to $3,000 to Docklight in exchange for mutual releases and a dismissal of the pending Docklight litigation claims.
\n\u00a0
\nMediPharm / HEXO Litigation Settlement
\n\u00a0
\nIn July 2022, MediPharm Labs Inc. (\u201cMediPharm) and Peter Hwang obtained a judgement for damages against HEXO Inc. in an amount equal to CAD $9,800, together with costs and interest, in connection with HEXO\u2019s alleged failure to pay for certain products. Subsequent to Tilray\u2019s acquisition of HEXO, on October 2, 2023, MediPharm, HEXO and Tilray reached a settlement of the MediPharm judgment. Specifically, the terms of the settlement consisted of the following: (i) CAD $3,000 cash payment to MediPharm; (ii) issuance to MediPharm of a product supply credit for CAD $1,000 for the purchase of Tilray cannabis products at market pricing; (iii) Tilray acquired all of the outstanding shares of a MediPharm subsidiary in exchange for the issuance by Tilray of 1,573,152 Tilray common shares; (iv) payment of CAD $210 to Peter Hwang; and (v) dismissal of the MediPharm judgment and mutual releases of all claims.
\n\u00a0
\nSummary of litigation accruals\u00a0
\n\u00a0
\nAs described in Note 11 (Accounts payable and accrued liabilities), the total litigation\u00a0expense accrual included in accrued liabilities as of\u00a0 November 30, 2023 was\u00a0$25,338\u00a0to cover various ongoing litigation matters that are probable and estimable ( May 31, 2023 - $25,000). During the six months ended November 30, 2023, the Company assumed\u00a0$12,253\u00a0of litigation accruals from the acquisition of HEXO, several of which were settled in the period as described above.\u00a0 The Company did assume any litigation accruals from the Craft Acquisition.\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1446","factDimensions":{"xbrl:concept":"srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 183,238 | \u00a0 | \u00a0 | $ | 12,993 | \u00a0 | \u00a0 | $ | 45,968 | \u00a0 | \u00a0 | $ | 8,953 | \u00a0 | \u00a0 | $ | 10,332 | \u00a0 | \u00a0 | $ | 104,992 | \u00a0 |
| Convertible notes | \u00a0 | \u00a0 | 309,240 | \u00a0 | \u00a0 | \u00a0 | 136,740 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 172,500 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 56,972 | \u00a0 | \u00a0 | \u00a0 | 33,584 | \u00a0 | \u00a0 | \u00a0 | 21,388 | \u00a0 | \u00a0 | \u00a0 | 2,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Construction commitments | \u00a0 | \u00a0 | 822 | \u00a0 | \u00a0 | \u00a0 | 822 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 550,272 | \u00a0 | \u00a0 | $ | 184,139 | \u00a0 | \u00a0 | $ | 67,356 | \u00a0 | \u00a0 | $ | 10,953 | \u00a0 | \u00a0 | $ | 182,832 | \u00a0 | \u00a0 | $ | 104,992 | \u00a0 |
Note 20. Net revenue
\n\u00a0
\nThe Company reports its net revenue in\u00a0\u00a0reporting segments: cannabis, distribution, beverage alcohol and wellness.
\n\u00a0
\nNet revenue is comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Cannabis revenue | \u00a0 | $ | 94,556 | \u00a0 | \u00a0 | $ | 66,696 | \u00a0 | \u00a0 | $ | 191,440 | \u00a0 | \u00a0 | $ | 142,385 | \u00a0 |
| Cannabis excise taxes | \u00a0 | \u00a0 | (27,442 | ) | \u00a0 | \u00a0 | (16,798 | ) | \u00a0 | \u00a0 | (53,993 | ) | \u00a0 | \u00a0 | (33,917 | ) |
| Net cannabis revenue | \u00a0 | \u00a0 | 67,114 | \u00a0 | \u00a0 | \u00a0 | 49,898 | \u00a0 | \u00a0 | \u00a0 | 137,447 | \u00a0 | \u00a0 | \u00a0 | 108,468 | \u00a0 |
| Beverage alcohol revenue | \u00a0 | \u00a0 | 49,651 | \u00a0 | \u00a0 | \u00a0 | 23,405 | \u00a0 | \u00a0 | \u00a0 | 74,990 | \u00a0 | \u00a0 | \u00a0 | 45,268 | \u00a0 |
| Beverage alcohol excise taxes | \u00a0 | \u00a0 | (3,146 | ) | \u00a0 | \u00a0 | (2,010 | ) | \u00a0 | \u00a0 | (4,323 | ) | \u00a0 | \u00a0 | (3,219 | ) |
| Net beverage alcohol revenue | \u00a0 | \u00a0 | 46,505 | \u00a0 | \u00a0 | \u00a0 | 21,395 | \u00a0 | \u00a0 | \u00a0 | 70,667 | \u00a0 | \u00a0 | \u00a0 | 42,049 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 67,223 | \u00a0 | \u00a0 | \u00a0 | 60,188 | \u00a0 | \u00a0 | \u00a0 | 136,380 | \u00a0 | \u00a0 | \u00a0 | 120,773 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 12,929 | \u00a0 | \u00a0 | \u00a0 | 12,655 | \u00a0 | \u00a0 | \u00a0 | 26,226 | \u00a0 | \u00a0 | \u00a0 | 26,057 | \u00a0 |
| Total | \u00a0 | $ | 193,771 | \u00a0 | \u00a0 | $ | 144,136 | \u00a0 | \u00a0 | $ | 370,720 | \u00a0 | \u00a0 | $ | 297,347 | \u00a0 |
\u00a0\u00a0
\n "}]},{"name":"rpt:f-1487","factDimensions":{"xbrl:concept":"us-gaap:DisaggregationOfRevenueTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Cannabis revenue | \u00a0 | $ | 94,556 | \u00a0 | \u00a0 | $ | 66,696 | \u00a0 | \u00a0 | $ | 191,440 | \u00a0 | \u00a0 | $ | 142,385 | \u00a0 |
| Cannabis excise taxes | \u00a0 | \u00a0 | (27,442 | ) | \u00a0 | \u00a0 | (16,798 | ) | \u00a0 | \u00a0 | (53,993 | ) | \u00a0 | \u00a0 | (33,917 | ) |
| Net cannabis revenue | \u00a0 | \u00a0 | 67,114 | \u00a0 | \u00a0 | \u00a0 | 49,898 | \u00a0 | \u00a0 | \u00a0 | 137,447 | \u00a0 | \u00a0 | \u00a0 | 108,468 | \u00a0 |
| Beverage alcohol revenue | \u00a0 | \u00a0 | 49,651 | \u00a0 | \u00a0 | \u00a0 | 23,405 | \u00a0 | \u00a0 | \u00a0 | 74,990 | \u00a0 | \u00a0 | \u00a0 | 45,268 | \u00a0 |
| Beverage alcohol excise taxes | \u00a0 | \u00a0 | (3,146 | ) | \u00a0 | \u00a0 | (2,010 | ) | \u00a0 | \u00a0 | (4,323 | ) | \u00a0 | \u00a0 | (3,219 | ) |
| Net beverage alcohol revenue | \u00a0 | \u00a0 | 46,505 | \u00a0 | \u00a0 | \u00a0 | 21,395 | \u00a0 | \u00a0 | \u00a0 | 70,667 | \u00a0 | \u00a0 | \u00a0 | 42,049 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 67,223 | \u00a0 | \u00a0 | \u00a0 | 60,188 | \u00a0 | \u00a0 | \u00a0 | 136,380 | \u00a0 | \u00a0 | \u00a0 | 120,773 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 12,929 | \u00a0 | \u00a0 | \u00a0 | 12,655 | \u00a0 | \u00a0 | \u00a0 | 26,226 | \u00a0 | \u00a0 | \u00a0 | 26,057 | \u00a0 |
| Total | \u00a0 | $ | 193,771 | \u00a0 | \u00a0 | $ | 144,136 | \u00a0 | \u00a0 | $ | 370,720 | \u00a0 | \u00a0 | $ | 297,347 | \u00a0 |
Note 21. Cost of goods sold
\n\u00a0
\nCost of goods sold is comprised of:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n For the three months | \n \u00a0 | \n\u00a0 | \n For the six months | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n||||
| Cannabis costs | \n \u00a0 | \n$ | \n46,472 | \n\u00a0 | \n\u00a0 | \n$ | \n28,577 | \n\u00a0 | \n\u00a0 | \n$ | \n96,989 | \n\u00a0 | \n\u00a0 | \n$ | \n57,438 | \n\u00a0 | \n
| Beverage alcohol costs | \n \u00a0 | \n\u00a0 | \n30,513 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n11,420 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n41,779 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n22,269 | \n\u00a0 | \n
| Distribution costs | \n \u00a0 | \n\u00a0 | \n60,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n52,495 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n121,615 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n107,479 | \n\u00a0 | \n
| Wellness costs | \n \u00a0 | \n\u00a0 | \n9,230 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,762 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,732 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,665 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n146,362 | \n\u00a0 | \n\u00a0 | \n$ | \n101,254 | \n\u00a0 | \n\u00a0 | \n$ | \n279,115 | \n\u00a0 | \n\u00a0 | \n$ | \n205,851 | \n\u00a0 | \n
\u00a0 \u00a0 \u00a0
\n "}]},{"name":"rpt:f-1525","factDimensions":{"xbrl:concept":"tlry:ScheduleOfCostOfGoodsSoldTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n For the three months | \n \u00a0 | \n\u00a0 | \n For the six months | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n||||
| Cannabis costs | \n \u00a0 | \n$ | \n46,472 | \n\u00a0 | \n\u00a0 | \n$ | \n28,577 | \n\u00a0 | \n\u00a0 | \n$ | \n96,989 | \n\u00a0 | \n\u00a0 | \n$ | \n57,438 | \n\u00a0 | \n
| Beverage alcohol costs | \n \u00a0 | \n\u00a0 | \n30,513 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n11,420 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n41,779 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n22,269 | \n\u00a0 | \n
| Distribution costs | \n \u00a0 | \n\u00a0 | \n60,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n52,495 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n121,615 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n107,479 | \n\u00a0 | \n
| Wellness costs | \n \u00a0 | \n\u00a0 | \n9,230 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,762 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,732 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,665 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n146,362 | \n\u00a0 | \n\u00a0 | \n$ | \n101,254 | \n\u00a0 | \n\u00a0 | \n$ | \n279,115 | \n\u00a0 | \n\u00a0 | \n$ | \n205,851 | \n\u00a0 | \n
Note 22. General and administrative expenses
\n\u00a0
\nGeneral and administrative expenses are comprised of:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n For the three months | \n \u00a0 | \n\u00a0 | \n For the six months | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n||||
| Executive compensation | \n \u00a0 | \n$ | \n3,324 | \n\u00a0 | \n\u00a0 | \n$ | \n3,050 | \n\u00a0 | \n\u00a0 | \n$ | \n6,985 | \n\u00a0 | \n\u00a0 | \n$ | \n6,605 | \n\u00a0 | \n
| Office and general | \n \u00a0 | \n\u00a0 | \n8,065 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,383 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,233 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n13,212 | \n\u00a0 | \n
| Salaries and wages | \n \u00a0 | \n\u00a0 | \n15,795 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,151 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n28,909 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,786 | \n\u00a0 | \n
| Stock-based compensation | \n \u00a0 | \n\u00a0 | \n8,201 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,943 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n20,136 | \n\u00a0 | \n
| Insurance | \n \u00a0 | \n\u00a0 | \n2,499 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,726 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,348 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,429 | \n\u00a0 | \n
| Professional fees | \n \u00a0 | \n\u00a0 | \n2,503 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,730 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,002 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,220 | \n\u00a0 | \n
| (Gain) loss on sale of capital assets | \n \u00a0 | \n\u00a0 | \n(23 | \n) | \n\u00a0 | \n\u00a0 | \n(64 | \n) | \n\u00a0 | \n\u00a0 | \n(20 | \n) | \n\u00a0 | \n\u00a0 | \n13 | \n\u00a0 | \n
| Travel and accommodation | \n \u00a0 | \n\u00a0 | \n1,374 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,219 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,481 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,380 | \n\u00a0 | \n
| Rent | \n \u00a0 | \n\u00a0 | \n1,575 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n740 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,433 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,605 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n43,313 | \n\u00a0 | \n\u00a0 | \n$ | \n37,878 | \n\u00a0 | \n\u00a0 | \n$ | \n83,829 | \n\u00a0 | \n\u00a0 | \n$ | \n78,386 | \n\u00a0 | \n
\u00a0
\n \n \n "}]},{"name":"rpt:f-1547","factDimensions":{"xbrl:concept":"tlry:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n For the three months | \n \u00a0 | \n\u00a0 | \n For the six months | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n\u00a0 | \n ended November 30, | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2022 | \n \u00a0 | \n||||
| Executive compensation | \n \u00a0 | \n$ | \n3,324 | \n\u00a0 | \n\u00a0 | \n$ | \n3,050 | \n\u00a0 | \n\u00a0 | \n$ | \n6,985 | \n\u00a0 | \n\u00a0 | \n$ | \n6,605 | \n\u00a0 | \n
| Office and general | \n \u00a0 | \n\u00a0 | \n8,065 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,383 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,233 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n13,212 | \n\u00a0 | \n
| Salaries and wages | \n \u00a0 | \n\u00a0 | \n15,795 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,151 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n28,909 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,786 | \n\u00a0 | \n
| Stock-based compensation | \n \u00a0 | \n\u00a0 | \n8,201 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,943 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n20,136 | \n\u00a0 | \n
| Insurance | \n \u00a0 | \n\u00a0 | \n2,499 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,726 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,348 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,429 | \n\u00a0 | \n
| Professional fees | \n \u00a0 | \n\u00a0 | \n2,503 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,730 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,002 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,220 | \n\u00a0 | \n
| (Gain) loss on sale of capital assets | \n \u00a0 | \n\u00a0 | \n(23 | \n) | \n\u00a0 | \n\u00a0 | \n(64 | \n) | \n\u00a0 | \n\u00a0 | \n(20 | \n) | \n\u00a0 | \n\u00a0 | \n13 | \n\u00a0 | \n
| Travel and accommodation | \n \u00a0 | \n\u00a0 | \n1,374 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,219 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,481 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,380 | \n\u00a0 | \n
| Rent | \n \u00a0 | \n\u00a0 | \n1,575 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n740 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,433 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,605 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n43,313 | \n\u00a0 | \n\u00a0 | \n$ | \n37,878 | \n\u00a0 | \n\u00a0 | \n$ | \n83,829 | \n\u00a0 | \n\u00a0 | \n$ | \n78,386 | \n\u00a0 | \n
Note 23. Restructuring charges
\n\u00a0
\nIn connection with the execution of our acquisition strategy and strategic transactions, the Company has incurred restructuring and exit costs associated with the integration efforts of these non-recurring transactions. The Company recognized $2,655\u00a0and $3,570\u00a0of restructuring charges for the three and six months ended November 30, 2023, compared to $8,064\u00a0and $8,064 for prior year comparative periods.\u00a0The Company approves detailed restructuring initiative plans at the executive level and recognizes these expenses in the period in which the plan has been committed to. All amounts incurred as of November 30\u00a02023, have been paid.\u00a0
\n\u00a0
\nWithin the Cannabis reporting unit, three restructuring plans have been initiated as follows;\u00a0\u00a0HEXO acquisition related charges which is expected to take place 24 months from the acquisition date, Truss acquisition related charges which is expected to take place 18 months from the acquisition date and the Canadian business cost reduction plan, which concluded during the quarter. In the six month period ended November 30, 2023, the following expenses were recognized, $1,221 of employee termination benefits for the HEXO acquisition plan, $1,586 of restructuring charges related to the costs of exiting the facility until the new business has resumed for the Truss acquisition plan and $281 of employee termination benefits for the Canadian business cost reduction plan.
\n\u00a0
\nWithin the Distribution reporting unit, the Company executed a cost optimization plan during the three months ended November 30, 2023. It is expected that this plan will be completed within the current fiscal year. In the six month period ended November 30, 2023, the Company recognized $482 related to employee termination benefits in association with executing this plan.
\n\u00a0
\nFor the prior period three and six months\u00a0ended November 30, 2022, the Company recognized\u00a0$8,064 and $8,064 which was comprised of $1,599 of exit cost and $2,758 for inventory adjustments from the termination of our producer partnership in Uruguay due to a breach of the underlying contract in our International cannabis business. Additionally, amounts related to the Tilray-Aphria Arrangement Agreement for the closure of our Canadian cannabis facility in Enniskillen of $1,512 million were incurred. The Company also incurred $2,195 million of write-offs from the exit of our medical device reprocessing business in our distribution reporting segment. These exit costs were completed in the prior year quarter ended November 30, 2022, and did not have on going impacts in the six months ended November 30, 2023.\u00a0
\n\u00a0
\n "}]},{"name":"rpt:f-1589","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2655000","decimals":-3}]},{"name":"rpt:f-1590","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3570000","decimals":-4}]},{"name":"rpt:f-1591","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"8064000","decimals":-3}]},{"name":"rpt:f-1592","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"8064000","decimals":-3}]},{"name":"rpt:f-1593","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:HexoAcquisitionMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:EmployeeSeveranceMember"},"factValues":[{"value":"1221000","decimals":-3}]},{"name":"rpt:f-1594","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:TrussBeverageCompanyMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember"},"factValues":[{"value":"1586000","decimals":-3}]},{"name":"rpt:f-1595","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:EmployeeSeveranceMember","us-gaap:RestructuringPlanAxis":"tlry:CostReductionMember"},"factValues":[{"value":"281000","decimals":-3}]},{"name":"rpt:f-1596","factDimensions":{"xbrl:concept":"us-gaap:RestructuringAndRelatedCostExpectedCost1","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringPlanAxis":"tlry:CostOptimizationMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"3000","decimals":-3}]},{"name":"rpt:f-1597","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:OneTimeTerminationBenefitsMember","us-gaap:RestructuringPlanAxis":"tlry:CostOptimizationMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"482000","decimals":-3}]},{"name":"rpt:f-1598","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2022-09-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringPlanAxis":"tlry:CostOptimizationMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"8064000","decimals":-3}]},{"name":"rpt:f-1599","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringPlanAxis":"tlry:CostOptimizationMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"8064000","decimals":-3}]},{"name":"rpt:f-1600","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:RestructuringPlanAxis":"tlry:CostOptimizationMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"1599000","decimals":-3}]},{"name":"rpt:f-1601","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:ContractTerminationMember","us-gaap:RestructuringPlanAxis":"tlry:CostOptimizationMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"2758000","decimals":-3}]},{"name":"rpt:f-1602","factDimensions":{"xbrl:concept":"us-gaap:RestructuringAndRelatedCostIncurredCost","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","srt:StatementGeographicalAxis":"country:CA"},"factValues":[{"value":"1512000000","decimals":-6}]},{"name":"rpt:f-1603","factDimensions":{"xbrl:concept":"us-gaap:RestructuringAndRelatedCostIncurredCost","xbrl:period":"2022-06-01T00:00:00/2022-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"2195000000","decimals":-6}]},{"name":"rpt:f-1604","factDimensions":{"xbrl:concept":"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 24. Non-operating income (expense)
\n\u00a0
\nNon-operating income (expense) is comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Change in fair value of convertible debenture payable | \u00a0 | $ | (3,894 | ) | \u00a0 | $ | (12,698 | ) | \u00a0 | $ | (6,041 | ) | \u00a0 | $ | (20,582 | ) |
| Change in fair value of warrant liability | \u00a0 | \u00a0 | 6,247 | \u00a0 | \u00a0 | \u00a0 | 37 | \u00a0 | \u00a0 | \u00a0 | (1,951 | ) | \u00a0 | \u00a0 | 1,585 | \u00a0 |
| Foreign exchange loss (gain) | \u00a0 | \u00a0 | (1,024 | ) | \u00a0 | \u00a0 | 907 | \u00a0 | \u00a0 | \u00a0 | 5,243 | \u00a0 | \u00a0 | \u00a0 | (24,666 | ) |
| Loss on long-term investments | \u00a0 | \u00a0 | 459 | \u00a0 | \u00a0 | \u00a0 | (596 | ) | \u00a0 | \u00a0 | 350 | \u00a0 | \u00a0 | \u00a0 | (1,604 | ) |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | (967 | ) | \u00a0 | \u00a0 | (6,100 | ) | \u00a0 | \u00a0 | (1,182 | ) | \u00a0 | \u00a0 | (6,175 | ) |
| Total | \u00a0 | $ | 821 | \u00a0 | \u00a0 | $ | (18,450 | ) | \u00a0 | $ | (3,581 | ) | \u00a0 | $ | (51,442 | ) |
\u00a0
\nIncluded in other non-operating (losses) gains, net for\u00a0the three and six months ended November 30, 2023, are losses of $(967)\u00a0and $(1,182)\u00a0resulting from the\u00a0downside protection share issuance relating to the HTI note,\u00a0as described in Note 15\u00a0(Stockholders' equity) and the gain on the settlement of TLRY 23 Convertible Notes.
\n "}]},{"name":"rpt:f-1605","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Change in fair value of convertible debenture payable | \u00a0 | $ | (3,894 | ) | \u00a0 | $ | (12,698 | ) | \u00a0 | $ | (6,041 | ) | \u00a0 | $ | (20,582 | ) |
| Change in fair value of warrant liability | \u00a0 | \u00a0 | 6,247 | \u00a0 | \u00a0 | \u00a0 | 37 | \u00a0 | \u00a0 | \u00a0 | (1,951 | ) | \u00a0 | \u00a0 | 1,585 | \u00a0 |
| Foreign exchange loss (gain) | \u00a0 | \u00a0 | (1,024 | ) | \u00a0 | \u00a0 | 907 | \u00a0 | \u00a0 | \u00a0 | 5,243 | \u00a0 | \u00a0 | \u00a0 | (24,666 | ) |
| Loss on long-term investments | \u00a0 | \u00a0 | 459 | \u00a0 | \u00a0 | \u00a0 | (596 | ) | \u00a0 | \u00a0 | 350 | \u00a0 | \u00a0 | \u00a0 | (1,604 | ) |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | (967 | ) | \u00a0 | \u00a0 | (6,100 | ) | \u00a0 | \u00a0 | (1,182 | ) | \u00a0 | \u00a0 | (6,175 | ) |
| Total | \u00a0 | $ | 821 | \u00a0 | \u00a0 | $ | (18,450 | ) | \u00a0 | $ | (3,581 | ) | \u00a0 | $ | (51,442 | ) |
Note 25. Fair value measurements
\n\u00a0
\nFinancial instruments
\n\u00a0
\nThe Company has classified its financial instruments as described in Note 3 Significant accounting policies in our Annual Financial Statements.
\n\u00a0
\nThe carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.
\n\u00a0
\nAt November 30, 2023\u00a0and\u00a0 May 31, 2023\u00a0the Company had long-term debt of $4,472\u00a0and $3,280, respectively,\u00a0and the principal portion of convertible debentures payable of $309,240 and $464,070, respectively,\u00a0subject to fixed interest rates. The Company\u2019s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.
\n\u00a0
\n \n \nThe following tables present information about the Company\u2019s assets and liabilities that are measured at fair value on a recurring basis as of November 30, 2023 and\u00a0 May 31, 2023 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | November 30, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 143,373 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 143,373 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | 1,576 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 1,576 | \u00a0 | ||
| Marketable securities | \u00a0 | \u00a0 | 116,418 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 116,418 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | 74,681 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (3,768 | ) | \u00a0 | \u00a0 | (3,768 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (20,704 | ) | \u00a0 | \u00a0 | (20,704 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (128,399 | ) | \u00a0 | \u00a0 | (128,399 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 261,367 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (72,690 | ) | \u00a0 | $ | 188,677 | \u00a0 |
\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 206,632 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 206,632 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Marketable Securities | \u00a0 | \u00a0 | 241,897 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 241,897 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 103,401 | \u00a0 | \u00a0 | \u00a0 | 103,401 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 1,056 | \u00a0 | \u00a0 | \u00a0 | 1,088 | \u00a0 | \u00a0 | \u00a0 | 5,651 | \u00a0 | \u00a0 | \u00a0 | 7,795 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,817 | ) | \u00a0 | \u00a0 | (1,817 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (27,107 | ) | \u00a0 | \u00a0 | (27,107 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (120,568 | ) | \u00a0 | \u00a0 | (120,568 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 449,585 | \u00a0 | \u00a0 | $ | 1,088 | \u00a0 | \u00a0 | $ | (40,440 | ) | \u00a0 | $ | 410,233 | \u00a0 |
\u00a0
\nThe Company\u2019s financial assets and liabilities required to be measured on a recurring basis are its convertible notes receivable, equity investments measured at fair value, convertible debentures measured at fair value, acquisition-related contingent consideration, and warrant liability.
\n\u00a0
\nConvertible notes receivable and long-term investments are recorded at fair value. The estimated fair value is determined using the Black Scholes option pricing model, probability of legalization and is classified as Level\u00a03.
\n\u00a0
\nConvertible debentures payable are recorded at fair value when elected or required under US GAAP. Specifically, the APHA\u00a024\u00a0instrument's estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level\u00a03.\u00a0
\n\u00a0
\nCertain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level\u00a01. The\u00a0Company classified securities with observable inputs as Level\u00a02\u00a0and without a quoted market price as Level\u00a03.
\n\u00a0
\nThe warrants associated with the warrant liability are classified as Level\u00a03\u00a0derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders\u2019 equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.
\n\u00a0
\nThe contingent consideration from the acquisitions of SweetWater,\u00a0Montauk, and Truss due in\u00a0\u00a0 December 2023,\u00a0 December 2025, and upon the triggering event if met, respectively and are payable in cash, is determined by discounting future expected cash outflows at a discount rate in the range of\u00a05% - 11.4%, and probability of achievement of\u00a025% and 90%. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level\u00a03. During the six months ended November 30, 2023, a decrease in fair value of $10,584, inclusive of changes in foreign exchange,\u00a0was recognized and was comprised of\u00a0 a decrease of fair value of $13,218\u00a0for the contingent consideration from the Sweetwater acquisition as a result of a lower probability of achieving the incentive targets which was offset by\u00a0an increase in fair value of $2,411 for the contingent consideration from the Montauk\u00a0acquisition as a result of a higher probability of achieving the incentive targets. Lastly, the addition of $4,181 of contingent\u00a0consideration liability was assumed as part of the\u00a0Truss acquisition and an increase in fair value of\u00a0$223 as a result of foreign exchange.
\n\u00a0
\nThe balances of assets and liabilities categorized within Level\u00a03\u00a0of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:
\n\u00a0
\n \n \n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2023 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | ) | \u00a0 | $ | ) | \u00a0 | $ | ) | |||||
| Additions | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | ) | \u00a0 | \u00a0 | \u00a0 | |||||
| Disposals | \u00a0 | \u00a0 | (28,720 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | ) | \u00a0 | \u00a0 | ) | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | ) | |||||
| Impairments | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |||||
| Balance, November 30, 2023 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | ) | \u00a0 | $ | ) | \u00a0 | $ | ) |
\u00a0
\nThe unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | \u00a0 |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| APHA Convertible debentures | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 0.5 | \u00a0 |
| Warrant liability | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 1.3 | \u00a0 |
| Contingent consideration | \u00a0 | Discounted cash flows | \u00a0 | Discount rate, | \u00a0 | 5% - 11% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | achievement | \u00a0 | 25% - 90% | \u00a0 |
\u00a0
\nItems measured at fair value on a non-recurring basis
\n\u00a0
\nThe Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.
\n\u00a0
\nManagement reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company\u2019s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.
\n "}]},{"name":"rpt:f-1633","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"4472000","decimals":-3}]},{"name":"rpt:f-1634","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2023-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"3280000","decimals":-4}]},{"name":"rpt:f-1635","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"309240000","decimals":-4}]},{"name":"rpt:f-1636","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2023-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"464070000","decimals":-4}]},{"name":"rpt:f-1637","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | November 30, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 143,373 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 143,373 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | 1,576 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 1,576 | \u00a0 | ||
| Marketable securities | \u00a0 | \u00a0 | 116,418 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 116,418 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 74,681 | \u00a0 | \u00a0 | \u00a0 | 74,681 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (3,768 | ) | \u00a0 | \u00a0 | (3,768 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (20,704 | ) | \u00a0 | \u00a0 | (20,704 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (128,399 | ) | \u00a0 | \u00a0 | (128,399 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 261,367 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (72,690 | ) | \u00a0 | $ | 188,677 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 206,632 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 206,632 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Marketable Securities | \u00a0 | \u00a0 | 241,897 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 241,897 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 103,401 | \u00a0 | \u00a0 | \u00a0 | 103,401 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 1,056 | \u00a0 | \u00a0 | \u00a0 | 1,088 | \u00a0 | \u00a0 | \u00a0 | 5,651 | \u00a0 | \u00a0 | \u00a0 | 7,795 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,817 | ) | \u00a0 | \u00a0 | (1,817 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (27,107 | ) | \u00a0 | \u00a0 | (27,107 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (120,568 | ) | \u00a0 | \u00a0 | (120,568 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 449,585 | \u00a0 | \u00a0 | $ | 1,088 | \u00a0 | \u00a0 | $ | (40,440 | ) | \u00a0 | $ | 410,233 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2023 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | ) | \u00a0 | $ | ) | \u00a0 | $ | ) | |||||
| Additions | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | ) | \u00a0 | \u00a0 | \u00a0 | |||||
| Disposals | \u00a0 | \u00a0 | (28,720 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | ) | \u00a0 | \u00a0 | ) | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | ) | |||||
| Impairments | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |||||
| Balance, November 30, 2023 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | ) | \u00a0 | $ | ) | \u00a0 | $ | ) |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | \u00a0 |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| APHA Convertible debentures | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 0.5 | \u00a0 |
| Warrant liability | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 1.3 | \u00a0 |
| Contingent consideration | \u00a0 | Discounted cash flows | \u00a0 | Discount rate, | \u00a0 | 5% - 11% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | achievement | \u00a0 | 25% - 90% | \u00a0 |
Note 26. Segment reporting
\n\u00a0
\nInformation reported to the Chief Operating Decision Maker (\u201cCODM\u201d) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in\u00a0 reportable segments:\u00a0(1) cannabis operations, which encompasses the production, distribution,\u00a0sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (2) beverage alcohol operations, which encompasses the production, marketing and sale of beverage and beverage alcohol products, (3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to wholesale and pharmacy customers, and (4) wellness products, which encompasses hemp foods and hemp-based cannabidiol (\u201cCBD\u201d) consumer products. This structure is in line with how our Chief Operating Decision Maker (\u201cCODM\u201d) assesses our performance and allocates resources.
\n\u00a0
\nOperating segments have not been aggregated and no asset information is provided for the segments because the Company\u2019s CODM does not receive asset information by segment on a regular basis.\u00a0
\n\u00a0
\n \n \nSegment gross profit from external customers:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | $ | 67,114 | \u00a0 | \u00a0 | $ | 49,898 | \u00a0 | \u00a0 | $ | 137,447 | \u00a0 | \u00a0 | $ | 108,468 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 46,472 | \u00a0 | \u00a0 | \u00a0 | 28,577 | \u00a0 | \u00a0 | \u00a0 | 96,989 | \u00a0 | \u00a0 | \u00a0 | 57,438 | \u00a0 |
| Gross profit | \u00a0 | \u00a0 | 20,642 | \u00a0 | \u00a0 | \u00a0 | 21,321 | \u00a0 | \u00a0 | \u00a0 | 40,458 | \u00a0 | \u00a0 | \u00a0 | 51,030 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 67,223 | \u00a0 | \u00a0 | \u00a0 | 60,188 | \u00a0 | \u00a0 | \u00a0 | 136,380 | \u00a0 | \u00a0 | \u00a0 | 120,773 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 60,147 | \u00a0 | \u00a0 | \u00a0 | 52,495 | \u00a0 | \u00a0 | \u00a0 | 121,615 | \u00a0 | \u00a0 | \u00a0 | 107,479 | \u00a0 |
| Gross profit | \u00a0 | \u00a0 | 7,076 | \u00a0 | \u00a0 | \u00a0 | 7,693 | \u00a0 | \u00a0 | \u00a0 | 14,765 | \u00a0 | \u00a0 | \u00a0 | 13,294 | \u00a0 |
| Beverage alcohol | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage alcohol revenue | \u00a0 | \u00a0 | 46,505 | \u00a0 | \u00a0 | \u00a0 | 21,395 | \u00a0 | \u00a0 | \u00a0 | 70,667 | \u00a0 | \u00a0 | \u00a0 | 42,049 | \u00a0 |
| Beverage alcohol costs | \u00a0 | \u00a0 | 30,513 | \u00a0 | \u00a0 | \u00a0 | 11,420 | \u00a0 | \u00a0 | \u00a0 | 41,779 | \u00a0 | \u00a0 | \u00a0 | 22,269 | \u00a0 |
| Gross profit | \u00a0 | \u00a0 | 15,992 | \u00a0 | \u00a0 | \u00a0 | 9,975 | \u00a0 | \u00a0 | \u00a0 | 28,888 | \u00a0 | \u00a0 | \u00a0 | 19,780 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 12,929 | \u00a0 | \u00a0 | \u00a0 | 12,655 | \u00a0 | \u00a0 | \u00a0 | 26,226 | \u00a0 | \u00a0 | \u00a0 | 26,057 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 9,230 | \u00a0 | \u00a0 | \u00a0 | 8,762 | \u00a0 | \u00a0 | \u00a0 | 18,732 | \u00a0 | \u00a0 | \u00a0 | 18,665 | \u00a0 |
| Gross profit | \u00a0 | $ | 3,699 | \u00a0 | \u00a0 | $ | 3,893 | \u00a0 | \u00a0 | $ | 7,494 | \u00a0 | \u00a0 | $ | 7,392 | \u00a0 |
\u00a0
\nChannels of Cannabis revenue were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 6,288 | \u00a0 | \u00a0 | $ | 6,365 | \u00a0 | \u00a0 | $ | 12,430 | \u00a0 | \u00a0 | $ | 12,885 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 72,048 | \u00a0 | \u00a0 | \u00a0 | 52,390 | \u00a0 | \u00a0 | \u00a0 | 143,243 | \u00a0 | \u00a0 | \u00a0 | 110,745 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 4,289 | \u00a0 | \u00a0 | \u00a0 | 236 | \u00a0 | \u00a0 | \u00a0 | 9,584 | \u00a0 | \u00a0 | \u00a0 | 628 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 11,931 | \u00a0 | \u00a0 | \u00a0 | 7,705 | \u00a0 | \u00a0 | \u00a0 | 26,183 | \u00a0 | \u00a0 | \u00a0 | 18,127 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (27,442 | ) | \u00a0 | \u00a0 | (16,798 | ) | \u00a0 | \u00a0 | (53,993 | ) | \u00a0 | \u00a0 | (33,917 | ) |
| Total | \u00a0 | $ | 67,114 | \u00a0 | \u00a0 | $ | 49,898 | \u00a0 | \u00a0 | $ | 137,447 | \u00a0 | \u00a0 | $ | 108,468 | \u00a0 |
\u00a0
\nOn July 12, 2022, Tilray acquired the HEXO Convertible Note from HTI and also entered into a strategic alliance with HEXO Corp. (\u201cHEXO\u201d) as discussed in Note 8\u00a0(Convertible notes receivable) and Note 13\u00a0(Convertible debentures payable). In addition, the Company\u00a0and HEXO entered into various commercial transaction agreements. On June 22, 2023, the Company completed the HEXO Acquisition as described in Note 7\u00a0(Business acquisitions), and thus these commercial arrangements were terminated and HEXO's financial results were consolidated in the current period results.\u00a0\u00a0\u00a0\u00a0
\n\u00a0
\nIncluded in revenue from Canadian adult-use cannabis is \u00a0and $1,500\u00a0of advisory services revenue for the three and six months ended November 30, 2023, from the aforementioned HEXO commercial transaction agreements, compared to $7,882\u00a0and $15,635\u00a0of\u00a0advisory services revenue in the prior comparative period.
\n\u00a0
\n \n \nGeographic net revenue:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| North America | \u00a0 | $ | 114,619 | \u00a0 | \u00a0 | $ | 76,211 | \u00a0 | \u00a0 | $ | 208,140 | \u00a0 | \u00a0 | $ | 158,403 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 75,292 | \u00a0 | \u00a0 | \u00a0 | 62,715 | \u00a0 | \u00a0 | \u00a0 | 154,996 | \u00a0 | \u00a0 | \u00a0 | 128,756 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,860 | \u00a0 | \u00a0 | \u00a0 | 5,210 | \u00a0 | \u00a0 | \u00a0 | 7,584 | \u00a0 | \u00a0 | \u00a0 | 10,188 | \u00a0 |
| Total | \u00a0 | $ | 193,771 | \u00a0 | \u00a0 | $ | 144,136 | \u00a0 | \u00a0 | $ | 370,720 | \u00a0 | \u00a0 | $ | 297,347 | \u00a0 |
\u00a0
\nGeographic capital assets:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| North America | \u00a0 | $ | 506,151 | \u00a0 | \u00a0 | $ | 319,173 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 105,325 | \u00a0 | \u00a0 | \u00a0 | 107,131 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,611 | \u00a0 | \u00a0 | \u00a0 | 3,363 | \u00a0 |
| Total | \u00a0 | $ | 615,087 | \u00a0 | \u00a0 | $ | 429,667 | \u00a0 |
\u00a0
\nMajor customers are defined as customers that are materially significant\u00a0to the Company\u2019s annual revenues. For the three and six months ended November 30, 2023 and 2022, there were no major customers representing a material contribution\u00a0to\u00a0our quarterly revenues.
\n "}]},{"name":"rpt:f-1735","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | $ | 67,114 | \u00a0 | \u00a0 | $ | 49,898 | \u00a0 | \u00a0 | $ | 137,447 | \u00a0 | \u00a0 | $ | 108,468 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 46,472 | \u00a0 | \u00a0 | \u00a0 | 28,577 | \u00a0 | \u00a0 | \u00a0 | 96,989 | \u00a0 | \u00a0 | \u00a0 | 57,438 | \u00a0 |
| Gross profit | \u00a0 | \u00a0 | 20,642 | \u00a0 | \u00a0 | \u00a0 | 21,321 | \u00a0 | \u00a0 | \u00a0 | 40,458 | \u00a0 | \u00a0 | \u00a0 | 51,030 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 67,223 | \u00a0 | \u00a0 | \u00a0 | 60,188 | \u00a0 | \u00a0 | \u00a0 | 136,380 | \u00a0 | \u00a0 | \u00a0 | 120,773 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 60,147 | \u00a0 | \u00a0 | \u00a0 | 52,495 | \u00a0 | \u00a0 | \u00a0 | 121,615 | \u00a0 | \u00a0 | \u00a0 | 107,479 | \u00a0 |
| Gross profit | \u00a0 | \u00a0 | 7,076 | \u00a0 | \u00a0 | \u00a0 | 7,693 | \u00a0 | \u00a0 | \u00a0 | 14,765 | \u00a0 | \u00a0 | \u00a0 | 13,294 | \u00a0 |
| Beverage alcohol | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage alcohol revenue | \u00a0 | \u00a0 | 46,505 | \u00a0 | \u00a0 | \u00a0 | 21,395 | \u00a0 | \u00a0 | \u00a0 | 70,667 | \u00a0 | \u00a0 | \u00a0 | 42,049 | \u00a0 |
| Beverage alcohol costs | \u00a0 | \u00a0 | 30,513 | \u00a0 | \u00a0 | \u00a0 | 11,420 | \u00a0 | \u00a0 | \u00a0 | 41,779 | \u00a0 | \u00a0 | \u00a0 | 22,269 | \u00a0 |
| Gross profit | \u00a0 | \u00a0 | 15,992 | \u00a0 | \u00a0 | \u00a0 | 9,975 | \u00a0 | \u00a0 | \u00a0 | 28,888 | \u00a0 | \u00a0 | \u00a0 | 19,780 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 12,929 | \u00a0 | \u00a0 | \u00a0 | 12,655 | \u00a0 | \u00a0 | \u00a0 | 26,226 | \u00a0 | \u00a0 | \u00a0 | 26,057 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 9,230 | \u00a0 | \u00a0 | \u00a0 | 8,762 | \u00a0 | \u00a0 | \u00a0 | 18,732 | \u00a0 | \u00a0 | \u00a0 | 18,665 | \u00a0 |
| Gross profit | \u00a0 | $ | 3,699 | \u00a0 | \u00a0 | $ | 3,893 | \u00a0 | \u00a0 | $ | 7,494 | \u00a0 | \u00a0 | $ | 7,392 | \u00a0 |
| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 6,288 | \u00a0 | \u00a0 | $ | 6,365 | \u00a0 | \u00a0 | $ | 12,430 | \u00a0 | \u00a0 | $ | 12,885 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 72,048 | \u00a0 | \u00a0 | \u00a0 | 52,390 | \u00a0 | \u00a0 | \u00a0 | 143,243 | \u00a0 | \u00a0 | \u00a0 | 110,745 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 4,289 | \u00a0 | \u00a0 | \u00a0 | 236 | \u00a0 | \u00a0 | \u00a0 | 9,584 | \u00a0 | \u00a0 | \u00a0 | 628 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 11,931 | \u00a0 | \u00a0 | \u00a0 | 7,705 | \u00a0 | \u00a0 | \u00a0 | 26,183 | \u00a0 | \u00a0 | \u00a0 | 18,127 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (27,442 | ) | \u00a0 | \u00a0 | (16,798 | ) | \u00a0 | \u00a0 | (53,993 | ) | \u00a0 | \u00a0 | (33,917 | ) |
| Total | \u00a0 | $ | 67,114 | \u00a0 | \u00a0 | $ | 49,898 | \u00a0 | \u00a0 | $ | 137,447 | \u00a0 | \u00a0 | $ | 108,468 | \u00a0 |
| \u00a0 | \u00a0 | For the three months | \u00a0 | \u00a0 | For the six months | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | ended November 30, | \u00a0 | \u00a0 | ended November 30, | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2022 | \u00a0 | ||||
| North America | \u00a0 | $ | 114,619 | \u00a0 | \u00a0 | $ | 76,211 | \u00a0 | \u00a0 | $ | 208,140 | \u00a0 | \u00a0 | $ | 158,403 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 75,292 | \u00a0 | \u00a0 | \u00a0 | 62,715 | \u00a0 | \u00a0 | \u00a0 | 154,996 | \u00a0 | \u00a0 | \u00a0 | 128,756 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,860 | \u00a0 | \u00a0 | \u00a0 | 5,210 | \u00a0 | \u00a0 | \u00a0 | 7,584 | \u00a0 | \u00a0 | \u00a0 | 10,188 | \u00a0 |
| Total | \u00a0 | $ | 193,771 | \u00a0 | \u00a0 | $ | 144,136 | \u00a0 | \u00a0 | $ | 370,720 | \u00a0 | \u00a0 | $ | 297,347 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| North America | \u00a0 | $ | 506,151 | \u00a0 | \u00a0 | $ | 319,173 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 105,325 | \u00a0 | \u00a0 | \u00a0 | 107,131 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,611 | \u00a0 | \u00a0 | \u00a0 | 3,363 | \u00a0 |
| Total | \u00a0 | $ | 615,087 | \u00a0 | \u00a0 | $ | 429,667 | \u00a0 |
Note 27. Subsequent Events
\n\u00a0
\nOn December 15, 2023 and December 21, 2023,\u00a0the Company exchanged\u00a0$18,500\u00a0aggregate principal of its APHA 24 Notes for cancellation by issuing 9,601,538\u00a0shares.\u00a0
\n\u00a0
\nOn January 5, 2024, the Company obtained a Waiver from its lender as\u00a0420 was not in compliance with the leverage ratio covenant under the 420 Secured Credit Agreement.\u00a0See \u201c420 Credit Agreement\u201d discussed in Part II, Item\u00a05. Other Information.
\n\u00a0
\nOn January 5, 2024, Aphria Inc. (\u201cAphria\u201d), a wholly-owned subsidiary of the Company, entered into an Amended and Restated Wholesale Cannabis Supply Agreement (the \u201cSupply Agreement\u201d) with 1974568 Ontario Limited (\u201cAphria Diamond\u201d), Aphria\u2019s joint venture with Double Diamond Holdings Ltd. The Supply Agreement amends and restates the existing supply agreement, effective as of September 1, 2023, and amends certain terms relating to pricing and product classes. See \u201cAphria Diamond Amended Supply Agreement\u201d discussed in Part II, Item\u00a05. Other Information.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1839","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentRepurchaseAmount","xbrl:period":"2023-12-22T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:APHA24Member","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"18500000","decimals":-5}]},{"name":"rpt:f-1840","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesToRepurchaseConvertibleDebt","xbrl:period":"2023-12-15T00:00:00/2023-12-22T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"tlry:APHA24Member","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"9601538"}]},{"name":"rpt:f-1841","factDimensions":{"xbrl:concept":"ecd:MtrlTermsOfTrdArrTextBlock","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n \n\u00a0
\n420 Credit Agreement
\n\u00a0
\nOn January 5, 2024, the Company\u2019s wholly-owned subsidiary, Four Twenty Corporation (the \u201cBorrower\u201d), entered into a Waiver (the \u201cWaiver\u201d) to that certain Credit Agreement dated as of June 30, 2023 (the \u201c420 Credit Agreement\u201d) by and among the Borrower, Bank of America, N.A., in its capacity as Administrative Agent (in such capacity, the \u201cAdministrative Agent\u201d), and certain other guarantors and lenders thereto. The Waiver provides for a\u00a0waiver of a potential event of default relating to the \u201cConsolidated Leverage Ratio\u201d financial covenant contained in the 420 Credit Agreement. The foregoing description of the Waiver does purport to be complete and is qualified in its entirety by the full text of the Waiver, which is being filed as Exhibit 10.2\u00a0to this quarterly report on Form 10-Q for the quarter ended November 30, 2023.
\n\u00a0
\nAphria Diamond Amended Supply Agreement
\n\u00a0
\nOn January 5, 2024, Aphria Inc. (\u201cAphria\u201d), a wholly-owned subsidiary of the Company, entered into an Amended and Restated Wholesale Cannabis Supply Agreement (the \u201cSupply Agreement\u201d) with 1974568 Ontario Limited (\u201cAphria Diamond\u201d), Aphria\u2019s joint venture with Double Diamond Holdings Ltd.
\n\u00a0
\nThe Supply Agreement amends and restates the existing supply agreement, effective as of September 1, 2023, and amends certain terms relating to pricing and product classes. Pursuant to the Supply Agreement, Aphria will purchase cannabis products on a non-exclusive basis from Aphria Diamond grown at Aphria Diamond\u2019s Leamington, Ontario cannabis cultivation facility (the \u201cAphria Diamond Facility\u201d) and will supply Aphria Diamond with rooted cuttings to be used for cultivation of cannabis products at the Aphria Diamond Facility. Aphria Diamond agrees to exclusively supply cannabis products to Aphria, subject to limited exceptions to allocate un-utilized cultivation capacity at the Aphria Diamond Facility. The foregoing summary of the Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the Supply Agreement, a copy of which is attached hereto as Exhibit 10.1\u00a0and incorporated herein by reference.
\n\u00a0
\n \n \n "}]}]}}